

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau



(10) International Publication Number

WO 2018/140970 A1

(43) International Publication Date

02 August 2018 (02.08.2018)

(51) International Patent Classification:

A61K 35/76 (2015.01) C12N 15/86 (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2018/016025

(22) International Filing Date:

30 January 2018 (30.01.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/452,075 30 January 2017 (30.01.2017) US

(71) Applicant: EPICENTRX, INC. [US/US]; 4445 Eastgate Mall, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: REID, Tony, R.; 5517 Carriage Court, San Diego, CA 92130 (US). ORONSKY, Bryan, T.; 28540 Matadero Creek Lane, Los Altos Hills, CA 94022 (US). HEDJRAN, Farah; 4445 Eastgate Mall, Suite 200, San Diego, CA 92121 (US). LARSON, Christopher; 3815 Lebon Dr., Apt. 335, San Diego, CA 92122 (US).

(74) Agent: DAVENPORT, Andrew, M. et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS

(57) Abstract: The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.

**TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS****CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims the benefit of, and priority to, U.S. Provisional Patent Application serial number 62/452,075 filed January 30, 2017, which is hereby incorporated by reference herein in its entirety.

**FIELD OF THE INVENTION**

[0002] The field of the invention is molecular biology and virology, specifically modified viruses that preferentially infect hyperproliferative and/or non-growth arrested cells.

**BACKGROUND**

10 [0003] Despite extensive knowledge of the underlying molecular mechanisms that cause cancer, most advanced cancers remain incurable with current chemotherapy and radiation protocols. Oncolytic viruses have emerged as a platform technology that has the potential to significantly augment current standard treatment for a variety of malignancies (Kumar, S. *et al.* (2008) CURRENT OPINION IN MOLECULAR THERAPEUTICS 10(4):371-379; Kim, D. (2001) EXPERT OPINION ON BIOLOGICAL THERAPY 1(3):525-538; Kim D. (2000) ONCOGENE 19(56):6660-6669). These viruses have shown promise as oncolytic agents that not only directly destroy malignant cells via an infection-to-reproduction-to-lysis chain reaction but also indirectly induce anti-tumor immunity. These immune stimulatory properties have been augmented with the insertion of therapeutic transgenes that are copied and expressed each time 20 the virus replicates.

[0004] Previously developed oncolytic viruses include the oncolytic serotype 5 adenovirus (Ad5) referred to as TAV-255 that is transcriptionally attenuated in normal cells but transcriptionally active in cancer cells (see, PCT Publication No. WO2010/101921). It is believed that the mechanism by which the TAV-255 vector achieves this tumor selectivity is 25 through targeted deletion of three transcriptional factor (TF) binding sites for the transcription factors Pea3 and E2F, proteins that regulate adenovirus expression of E1a, the earliest gene to be transcribed after virus entry into the host cell, through binding to specific DNA sequences.

**[0005]** Despite the efforts to date, there is a need for improved oncolytic viruses that, in particular, exhibit tumor-selective replication, viral mediated lysis, and/or therapeutic transgene expression for treating cancers and hyperproliferative disorders in human patients.

5

## SUMMARY OF THE INVENTION

**[0006]** The invention is based, in part, upon the discovery that, for certain viral promoters, the TATA and/or CAAT box, while necessary to drive transcription in normal, healthy cells, is dispensable for active transcription in cancerous cells.

**[0007]** Accordingly, in one aspect, the invention provides a recombinant virus comprising:

10 (i) a modified TATA box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell; and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a

15 hyperproliferative and/or non-growth arrested cell.

**[0008]** In another aspect, the invention provides a recombinant virus comprising a modified TATA box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

20 **[0009]** In another aspect, the invention provides a recombinant virus comprising a modified CAAT box-based promoter operably linked to a gene, wherein the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

**[0010]** In certain embodiments of any of the foregoing recombinant viruses, the recombinant virus is selected from a recombinant vaccinia virus, adenovirus, adeno-associated virus (AAV), herpes simplex virus 1 (HSV1), myxoma virus, reovirus, poliovirus, vesicular stomatitis virus (VSV), measles virus (MV), and Newcastle disease virus (NDV). In certain embodiments, the recombinant virus is an adenovirus, *e.g.*, a type 5 adenovirus (Ad5) or a type 35 adenovirus (Ad35), *e.g.*, a type 5 adenovirus. In certain embodiments, the modified TATA

box-based promoter and/or the modified CAAT box-based promoter is an early gene promoter, *e.g.*, an E1a promoter, E1b promoter, or E4 promoter, *e.g.*, an E1a promoter.

5 [0011] In certain embodiments of any of the foregoing recombinant viruses, the modification included in the modified TATA box-based promoter comprises a deletion of the entire TATA box. In certain embodiments, the virus comprises a deletion of nucleotides corresponding to -27 to -24, -31 to -24, -44 to +54, or -146 to +54 of the adenovirus type 5 E1a promoter, which correspond, respectively, to nucleotides 471 to 474, 467 to 474, 454 to 551 and 352 to 551 of SEQ ID NO: 2, and to nucleotides 472 to 475, 468 to 475, 455 to 552, and 353 to 552 of SEQ ID NO: 8.

10 [0012] In certain embodiments, the virus comprises a deletion of nucleotides corresponding to -29 to -26, -33 to -26, -44 to +52, or -148 to +52 of the adenovirus type 5 E1a promoter. In certain embodiments, the virus comprises a deletion of nucleotides corresponding to nucleotides 471 to 475, 467 to 475, 446 to 551 and 352 to 551 of SEQ ID NO: 2.

15 [0013] In another aspect, the invention provides a recombinant virus, wherein the virus is a type 5 adenovirus, and the virus comprises a deletion of nucleotides corresponding to -27 to -24, -31 to -24, -44 to +54, or -146 to +54 of the adenovirus type 5 E1a promoter, which correspond, respectively, to nucleotides 471 to 474, 467 to 474, 454 to 551 and 352 to 551 of SEQ ID NO: 2, and to nucleotides 472 to 475, 468 to 475, 455 to 552, and 353 to 552 of SEQ ID NO: 8.

20 [0014] In another aspect, the invention provides a recombinant virus, wherein the virus is a type 5 adenovirus, and the virus comprises a deletion of nucleotides corresponding to -29 to -26, -33 to -26, -44 to +52, or -148 to +52 of the adenovirus type 5 E1a promoter or a deletion of nucleotides corresponding to nucleotides 471 to 475, 467 to 475, 446 to 551 and 352 to 551 of SEQ ID NO: 2.

25 [0015] In another aspect, the invention provides a recombinant virus, wherein the virus is a type 5 adenovirus, and the virus comprises a polynucleotide deletion that results in a recombinant type 5 adenovirus comprising the sequence CTAGGACTG (SEQ ID NO: 7), AGTGCCCCG (SEQ ID NO: 12), or TATTCCCCG (SEQ ID NO: 13), which result from joining the two polynucleotide sequences that would otherwise flank the deleted polynucleotide sequence.

5 [0016] In certain embodiments of any of the foregoing recombinant viruses, the modification included in the modified CAAT box-based promoter comprises a deletion of the entire CAAT box. In certain embodiments, the virus comprises a deletion of nucleotides corresponding to -76 to -68 of the adenovirus type 5 E1a promoter, which corresponds to nucleotides 422 to 430 of SEQ ID NO: 2, and to nucleotides 423 to 431 of SEQ ID NO: 8.

[0017] In another aspect, the invention provides a recombinant virus, wherein the virus is a type 5 adenovirus, and the virus comprises a deletion of nucleotides corresponding to -76 to -68 of the adenovirus type 5 E1a promoter, which corresponds to nucleotides 422 to 430 of SEQ ID NO: 2, and to nucleotides 423 to 431 of SEQ ID NO: 8.

10 [0018] In certain embodiments of any of the foregoing recombinant viruses, the virus comprises the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, or SEQ ID NO: 23, or a sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, or SEQ ID NO: 23.

15

20 [0019] In another aspect, the invention provides a recombinant virus, wherein the virus is a type 5 adenovirus, and the virus comprises a polynucleotide deletion that results in a recombinant type 5 adenovirus comprising the sequence TTCCGTGGCG (SEQ ID NO: 14), which results from joining the two polynucleotide sequences that would otherwise flank the deleted polynucleotide sequence.

[0020] In certain embodiments of any of the foregoing recombinant viruses, the virus comprises a deletion of nucleotides corresponding to 477 to 484 of the Ad35 genome.

25 [0021] In certain embodiments, any of the foregoing recombinant viruses may further comprise a nucleotide sequence encoding a therapeutic transgene. The therapeutic transgene may encode a therapeutic polypeptide, *e.g.*, an apoptotic agent, antibody, CTL responsive peptide, cytokine, cytolytic agent, cytotoxic agent, enzyme, heterologous antigen expressed on the surface of a tumor cell to elicit an immune response, immunostimulatory or immunomodulatory agent, interferon, lytic peptide, oncoprotein, polypeptide which catalyzes processes leading to cell death, polypeptide which complements genetic defects in somatic cells, tumor suppressor protein, vaccine antigen, and any combination thereof. The therapeutic transgene may encode a therapeutic nucleic acid, *e.g.*, an antisense RNA or a ribozyme. In

30

certain embodiments, the therapeutic transgene is selected from acetylcholine, an anti-PD-1 antibody heavy chain or light chain, an anti-PD-L1 antibody heavy chain or light chain, BORIS/CTCFL, CD19, CD20, CD80, CD86, CD137L, CD154, DKK1/Wnt, ICAM-1, IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-17, IL-23, IL-23A/p19, interferon-gamma, TGF- $\beta$ , a TGF- $\beta$  trap, FGF, IL-24, IL-27, IL-35, MAGE, NY-ESO-1, p53, and thymidine kinase. In certain embodiments, the therapeutic transgene is a TGF- $\beta$  trap. In certain embodiments, the recombinant virus comprises an E1b-19K and an E1b-55K start site, and the nucleotide sequence encoding the therapeutic transgene is inserted between the start site of E1b-19K and the start site of E1b-55K.

10 [0022] In certain embodiments, any of the foregoing recombinant viruses may comprise a deletion of at least one Pea3 binding site, or a functional portion thereof.

[0023] In certain embodiments, any of the foregoing recombinant viruses may selectively replicate in a hyperproliferative cell and/or a non-growth arrested cell. In certain embodiments, any of the foregoing recombinant viruses may selectively express E1a, E1b, and/or a therapeutic transgene in a hyperproliferative cell and/or a non-growth arrested cell. In certain embodiments, any of the foregoing recombinant viruses may selectively have cytolytic activity in a hyperproliferative cell and/or a non-growth arrested cell.

[0024] The hyperproliferative and/or non-growth arrested cell may be a cancer cell, endothelial cell, epidermal cell, fibroblast, and/or immune cell. The hyperproliferative and/or non-growth arrested cell may be a cancer cell, *e.g.*, an anal cancer, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, gynecologic cancer, head and neck cancer, hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer or thyroid cancer cell.

[0025] In another aspect, the invention provides a recombinant virus comprising any modified or deleted viral regulatory sequence that permits selective expression of the virus in a hyperproliferative and/or non-growth arrested cell.

**[0026]** In another aspect, the invention provides a pharmaceutical composition comprising any one or a combination of the foregoing recombinant viruses and at least one pharmaceutically acceptable carrier or diluent.

**[0027]** In another aspect, the invention provides a method of treating a hyperproliferative disease, in a subject. The method comprises administering to the subject an effective amount of a recombinant virus described herein to treat the hyperproliferative disease in the subject. In certain embodiments, the hyperproliferative disease is selected from cancer, atherosclerosis, rheumatoid arthritis, psoriasis, lupus, idiopathic pulmonary fibrosis, sclerodermapulmonary hypertension, asthma, kidney fibrosis, COPD, cystic fibrosis, DIP, UIP, macular degeneration, restenosis, retinopathies, hyperproliferative fibroblast disorders, scleroderma, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, glomerulopathies and cirrhosis.

**[0028]** In certain embodiments, the hyperproliferative disease is cancer. In certain embodiments, the cancer is selected from anal cancer, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, gynecologic cancer, head and neck cancer, hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer and thyroid cancer.

**[0029]** In another aspect, the invention provides a method of inhibiting tumor growth in a subject. The method comprises administering to the subject an effective amount of a recombinant virus described herein to inhibit proliferation of the tumor cell.

**[0030]** In another aspect, the invention provides a method of inhibiting proliferation of a tumor cell. The method comprises exposing the cell to an effective amount of a recombinant viruses described herein to inhibit proliferation of the tumor cell.

**[0031]** In each of the foregoing methods, the recombinant virus can, *e.g.*, be administered in combination with one or more therapies selected from surgery, radiation, chemotherapy, immunotherapy, hormone therapy, and virotherapy. In each of the foregoing methods, the

effective amount of the recombinant virus can comprise, *e.g.*,  $10^2$ - $10^{15}$  plaque forming units (pfus). In each of the foregoing methods, the subject can, *e.g.*, be a human, *e.g.*, a pediatric human, or an animal.

**[0032]** In each of the foregoing methods, the effective amount of the recombinant virus

5 may, *e.g.*, be identified by measuring an immune response to an antigen in the subject. In certain embodiments, the immune response to the antigen is measured by injecting the subject with the antigen at an injection site on the skin of the subject and measuring the size of an induration at the injection site.

**[0033]** In another aspect, the invention provides a method of expressing a therapeutic

10 transgene in a target cell. The method comprises exposing the cell to an effective amount of the recombinant virus described herein to express the target transgene.

**[0034]** In another aspect, the invention provides a method of engineering an oncolytic virus. The method comprises modifying a viral TATA box-based promoter operably linked to a gene such that the modified TATA box-based promoter lacks a functional TATA box and

15 permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

**[0035]** In another aspect, the invention provides a method of engineering an oncolytic

virus. The method comprises modifying a viral CAAT box-based promoter operably linked to a gene such that the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

20 **[0036]** In another aspect, the invention provides a method of engineering an oncolytic virus. The method comprises modifying a viral TATA box-based promoter operably linked to a gene such that the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell and/or modifying a viral CAAT box-based promoter operably linked to a gene such that the

25 modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

**[0037]** In another aspect, the invention provides an isolated nucleic acid comprising a

nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17,

SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, or SEQ ID NO: 23, or a sequence having

30 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%

sequence identity to SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, or SEQ ID NO: 23. In certain embodiments, the isolated nucleic acid comprises the nucleotide sequence of SEQ ID NO: 4. The invention provides host cells comprising one or more of the foregoing nucleic acids.

5 [0038] In another aspect, the invention provides a method of producing a recombinant virus. The method comprises: (a) growing one or more of the foregoing host cells under conditions so that the host cell produces the recombinant virus; and (b) purifying the recombinant virus.

10 [0039] These and other aspects and advantages of the invention are illustrated by the following figures, detailed description and claims.

#### DESCRIPTION OF THE DRAWINGS

[0040] The invention can be more completely understood with reference to the following drawings.

15 [0041] **FIG. 1A** depicts the nucleotide sequence of the 5' end of Ad-Δ350 (which includes deletions of both the TATA box and the CAAT box) up to the start codon of the E1a gene. The site of the 200 nucleotide deletion from the wild-type adenoviral sequence is denoted with a hyphen. **FIG. 1B** depicts the nucleotide sequence of the 5' end of Ad-TATA up to the start codon of the E1a gene. The site of the 8 nucleotide deletion from the wild-type adenoviral sequence is denoted with a hyphen. **FIG. 1C** depicts the nucleotide sequence of the 5' end of Ad-CAAT up to the start codon of the E1a gene. The site of the 9 nucleotide deletion from the wild-type adenoviral sequence is denoted with a hyphen. **FIG. 1D** depicts the nucleotide sequence of the 5' end of Ad-CAAT-TATA up to the start codon of the E1a gene. The site of the 9 nucleotide and 8 nucleotide deletions from the wild-type adenoviral sequence are denoted with hyphens. **FIG. 1E** depicts the nucleotide sequence of the 5' end of Ad-CAAT-mTATA up to the start codon of the E1a gene. The site of the 9 nucleotide and 4 nucleotide deletions from the wild-type adenoviral sequence are denoted with hyphens. **FIG. 1F** depicts the nucleotide sequence of the 5' end of wild-type Ad5 up to the start codon of the E1a gene. The CAAT box (GGTCAAAGT) and TATA box (TATTCTATA) are indicated with boxes.

20

25 [0042] **FIG. 2A** depicts a Western blot showing E1a expression levels in cancerous Panc-1 cells at the indicated hours following infection with Ad-Δ350 or Ad-TAV-255. **FIG. 2B** depicts

a Western blot showing E1a expression levels in non-cancerous WI-38 cells at the indicated hours following the infection with Ad-Δ350 or Ad-TAV-255. L represents ladder and CN represents non-infected control.

[0043] **FIG. 3A** depicts a Western blot showing E1a expression levels in cancerous Panc-1 cells 72 hours following infection with Ad-Δ350 or Ad-TAV-255 at a multiplicity of infection (MOI) of 3 or 5. **FIG. 3B** depicts a Western blot showing E1a expression levels in cancerous A549 cells 72 hours following infection with Ad-Δ350 or Ad-TAV-255 at a multiplicity of infection (MOI) of 3 or 5. L represents ladder and CN represents non-infected control.

[0044] **FIG. 4A** depicts crystal violet staining of cancerous HCT116 cells, Panc-1 cells, and A549 cells at the indicated time points following infection with Ad-Δ350 at the indicated MOI. **FIG. 4B** depicts crystal violet staining of non-cancerous MRC5 cells and WI38 cells 10 days following infection with Ad-Δ350 or Ad-TAV-255 at the indicated MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

[0045] **FIG. 5** depicts crystal violet staining of cancerous A549, Panc1, HCT116, and Hep3b cells as non-infected controls and three days after infection with Ad-CAAT or Ad-CAAT-mTATA at 5 MOI. Crystal violet stains viable cells blue.

[0046] **FIG. 6** depicts crystal violet staining of cancerous ADS-12, ASPC1, HT-29, and Hep3b cells as non-infected controls and three days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue.

[0047] **FIG. 7** depicts crystal violet staining of cancerous ADS-12, ASPC1, HT-29, and Hep3b cells as non-infected controls and four days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue.

[0048] **FIG. 8** depicts crystal violet staining of cancerous Panc1, A549, MeWo, and HCT-116 cells as non-infected controls and three days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue.

**[0049]** **FIG. 9** depicts crystal violet staining of cancerous Panc1, A549, MeWo, and HCT-116 cells as non-infected controls and four days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue.

**[0050]** **FIG. 10** depicts crystal violet staining of cancerous A549, HCT116, Hep3b, and Panc1 cells as non-infected controls and five days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue.

**[0051]** **FIG. 11** depicts crystal violet staining of cancerous MeWo, HT29, ADS12, and ASPC cells as non-infected controls and five days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue.

**[0052]** **FIG. 12** depicts crystal violet staining of non-cancerous WI38 cells as non-infected controls and four days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at the indicated MOI. Crystal violet stains viable cells blue.

**[0053]** **FIG. 13** depicts crystal violet staining of non-cancerous WI38 cells as non-infected controls and six days after infection with Ad-TATA, Ad-CAAT, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k at the indicated MOI. Crystal violet stains viable cells blue.

**[0054]** **FIG. 14** depicts crystal violet staining of cancerous Panc-1 cells, A549 cells, and ADS12 cells five days after infection with Ad-Δ350-Δ19k at the indicated MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

**[0055]** **FIG. 15** depicts crystal violet staining of cancerous Panc-1 cells, A549 cells, and ADS12 cells five days after infection with Ad-Δ350-GM-CSF at the indicated MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

**[0056]** **FIG. 16** depicts crystal violet staining of cancerous A549 cells three days after infection with Ad-Δ350-Δ19k, Ad-Δ350-mGM-CSF, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

**[0057]** **FIG. 17** depicts crystal violet staining of cancerous A549 cells five days after infection with Ad-Δ350-Δ19k, Ad-Δ350-mGM-CSF, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

**[0058]** **FIG. 18** depicts crystal violet staining of cancerous HCT116 cells three days after infection with Ad-Δ350-Δ19k, Ad-Δ350-mGM-CSF, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

5 **[0059]** **FIG. 19** depicts crystal violet staining of cancerous HCT116 cells five days after infection with Ad-Δ350-Δ19k, Ad-Δ350-mGM-CSF, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

**[0060]** **FIG. 20** depicts crystal violet staining of cancerous Hep3b cells three days after infection with Ad-Δ350-Δ19k, Ad-Δ350-mGM-CSF, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

10 **[0061]** **FIG. 21** depicts crystal violet staining of cancerous MeWo cells five days after infection with Ad-Δ350-Δ19k, Ad-Δ350-mGM-CSF, and Ad-TAV-Δ19k at 5 MOI. Crystal violet stains viable cells blue. CN represents non-infected control.

**[0062]** **FIG. 22** depicts a bar graph showing mGM-CSF expression as assayed by ELISA following infection of A549 cells with Ad-Δ350-Δ19k or Ad-Δ350-mGM-CSF at 10 MOI.

15 **[0063]** **FIG. 23** depicts a bar graph showing mGM-CSF expression as assayed by ELISA following infection of ADS12 cells with Ad-Δ350-Δ19k or Ad-Δ350-mGM-CSF at the indicated MOI.

20 **[0064]** **FIG. 24** depicts tumor volumes of mice carrying subcutaneous ADS-12 tumors that were treated with three intratumoral injections of either buffer, Ad-Δ350-Δ19k (denoted 350-19k), or Ad-TAV-Δ19k (denoted TAV-19k). Each line in the figure represents the tumor volume of an individual mouse.

**[0065]** **FIG. 25** is an image depicting the viral cytopathic effect arising from HEK-293 cells transfected with a human adenovirus type 35 genome including a deletion of the TATA box in the E1A promoter.

## DETAILED DESCRIPTION

**[0066]** Transcription requires the correct positioning of RNA polymerase II (RNA pol II) on a short sequence of DNA called a promoter. A promoter sequence frequently includes a highly conserved A/T-rich sequence called a TATA box, often flanked by G/C-rich sequences, located approximately 30 base pairs upstream of the start site of transcription. Genes that lack

an identifiable TATA box are typically housekeeping genes, and depend upon the transcription factor Sp1 for transcription, whereas genes containing a TATA box are typically highly regulated genes that respond to biologic response pathways. The TATA box is recognized by Transcription Factor IIB (TFIIB) and the TATA binding protein (TBP), which are required for the recruitment of RNA pol II. The central role of the TATA box in transcription is supported by experimental observations of impaired or inactivated transcription following the mutation or removal of a TATA box, *e.g.*, the removal of the TATA box in the promoter of the adenoviral E1a gene (Wu *et al.* (1987) NATURE 326(6112):512-5).

[0067] An additional sequence present in many promoters is a CAAT box. A CAAT box is typically located approximately 60-100 bases upstream of a gene's transcription start site and has the consensus sequence GG(T/C)CAATCT. The CAAT box is recognized by core binding factors (also referred to as nuclear factor Y or NF-Y) and CCAAT/enhancer binding proteins (C/EBPs).

[0068] The invention is based, in part, upon the discovery that for certain viral promoters, *e.g.*, the type 5 adenovirus (Ad5) E1a promoter, the TATA and/or CAAT box, while necessary to drive transcription in normal, healthy cells, is dispensable for active transcription in cancerous cells. Accordingly, in one aspect, the invention provides a recombinant virus comprising: (i) a modified TATA box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell; and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative cell and/or non-growth arrested. The TATA box-based promoter and the CAAT box-based promoter may be the same promoter (*e.g.*, the Ad5 E1a promoter), or may be different promoters.

[0069] In another aspect, the invention provides a recombinant virus comprising a modified TATA box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

[0070] In another aspect, the invention provides a recombinant virus comprising a modified CAAT box-based promoter operably linked to a gene, wherein the modified CAAT

box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative and/or non-growth arrested cell.

**[0071]** In another aspect, the invention provides a recombinant virus comprising any modified or deleted viral regulatory sequence that permits selective expression of the virus in a hyperproliferative and/or non-growth arrested cell. Exemplary viral regulatory sequences in addition to TATA and CAAT boxes include the Ad5 E1a initiator sequence and the Ad5 E1a promoter element downstream of the TATA box.

**[0072]** As used herein, “TATA box” refers to a nucleotide sequence that is capable of binding to a TATA binding protein (TBP). A TATA box typically comprises an A/T-rich 8-nucleotide segment containing a core sequence of TATAAA (SEQ ID NO: 1), wherein the 8-nucleotide segment is flanked by G/C-rich sequences, however, a TATA box may bear little resemblance to the typical TATA sequence.

**[0073]** As used herein, a “modified TATA box” refers to a TATA box that has a deletion, substitution, or addition of one or more nucleotides relative to a wild-type TATA box sequence.

**[0074]** As used herein, a “functional TATA box” refers to a TATA box that is capable of binding to a TBP, *e.g.*, a TATA box that has at least 100%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, or at least 40%, of the TBP binding activity of a corresponding wild-type TATA box sequence. As used herein, a “non-functional TATA box” refers to a TATA box that, *e.g.*, has less than 30%, less than 20%, less than 10%, or 0% of the TBP binding activity of a corresponding wild-type TATA box sequence. Assays for determining whether a TBP binds to a TATA box are known in the art. Exemplary binding assays include electrophoretic mobility shift assays, chromatin immunoprecipitation assays, and DNase footprinting assays.

**[0075]** As used herein, “TATA box-based promoter” refers to any gene promoter that contains a TATA box.

**[0076]** As used herein, a “modified TATA box-based promoter” refers to a TATA box-based promoter that has been modified by a deletion, substitution, or addition of one or more nucleotides. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of one or more nucleotides of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified

TATA box-based promoter consists of a deletion of one or more nucleotides of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of the entire TATA box of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included 5 in the modified TATA box-based promoter consists of a deletion of the entire TATA box of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of the entire TATA box-based promoter. In certain embodiments, the modification included in the modified TATA box-based promoter consists of a deletion of the entire TATA box-based promoter. In certain 10 embodiments, the modification included in the modified TATA box-based promoter does not comprise an addition of or a substitution with a separate, functional promoter sequence.

**[0077]** In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of from 1 to 300, from 1 to 200, from 1 to 100, from 1 to 75, from 1 to 50, from 1 to 25, from 1 to 10, from 1 to 8, from 1 to 4 nucleotides, from 4 to 300, from 4 to 200, from 4 to 150, from 4 to 100, from 4 to 75, from 4 to 50, from 4 to 25, from 4 to 15, from 4 to 8, from 8 to 300, from 8 to 200, from 8 to 150, from 8 to 100, from 8 to 75, from 8 to 50, from 8 to 25, from 8 to 10, from 10 to 300, from 10 to 200, from 10 to 150, from 10 to 100, from 10 to 75, from 10 to 50, from 10 to 25, from 25 to 300, from 25 to 200, from 25 to 150, from 25 to 100, from 25 to 75, from 25 to 50, from 50 to 300, from 50 to 200, from 50 to 20, 20 from 50 to 100, from 50 to 75, from 75 to 300, from 75 to 200, from 75 to 150, from 75 to 100, from 100 to 300, from 100 to 200, from 100 to 150, from 150 to 300, from 150 to 200, or from 200 to 300 nucleotides of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of about 10, about 25, about 50, about 75, about 100, about 150, about 200, or about 25 300 nucleotides of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of about 200 nucleotides of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of 1, 2, 3, 4, 5, 6, 7, 8, or 10 nucleotides of the wild-type TATA box-based promoter sequence. In certain embodiments, the modification included in the modified TATA box-based promoter comprises a deletion of 4 or 8 nucleotides of the wild-type TATA box-based promoter sequence.

**[0078]** As used herein, “CAAT box” refers to a nucleotide sequence that is capable of binding to a C/EBP or NF-Y protein. A CAAT box typically comprises a consensus sequence of GG(T/C)CAATCT.

**[0079]** As used herein, a “modified CAAT box” refers to a CAAT box that has a deletion, 5 substitution, or addition of one or more nucleotides relative to a wild-type CAAT box sequence.

**[0080]** As used herein, a “functional CAAT box” refers to a CAAT box that is capable of binding to a C/EBP or NF-Y protein, *e.g.*, a CAAT box that has at least 100%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, or at least 40%, of the a C/EBP or NF-Y 10 binding activity of a corresponding wild-type CAAT box sequence. As used herein, a “non-functional CAAT box” refers to a CAAT box that, *e.g.*, has less than 30%, less than 20%, less than 10%, or 0% of the a C/EBP or NF-Y binding activity of a corresponding wild-type CAAT box sequence. Assays for determining whether a C/EBP or NF-Y protein binds to a CAAT box are known in the art. Exemplary binding assays include electrophoretic mobility shift assays, 15 chromatin immunoprecipitation assays, and DNase footprinting assays.

**[0081]** As used herein, “CAAT box-based promoter” refers to any gene promoter that contains a CAAT box.

**[0082]** As used herein, a “modified CAAT box-based promoter” refers to a CAAT box-based promoter that has been modified by a deletion, substitution, or addition of one or more 20 nucleotides. In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of one or more nucleotides of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter consists of a deletion of one or more nucleotides of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the 25 modified CAAT box-based promoter comprises a deletion of the entire CAAT box of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter consists of a deletion of the entire CAAT box of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of the entire CAAT 30 box-based promoter. In certain embodiments, the modification included in the modified CAAT box-based promoter consists of a deletion of the entire CAAT box-based promoter. In certain

embodiments, the modification included in the modified CAAT box-based promoter does not comprise an addition of or a substitution with a separate, functional promoter sequence.

**[0083]** In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of from 1 to 300, from 1 to 200, from 1 to 100, from 1 to 5, from 1 to 50, from 1 to 25, from 1 to 10, from 1 to 8, from 1 to 4 nucleotides, from 4 to 300, from 4 to 200, from 4 to 150, from 4 to 100, from 4 to 75, from 4 to 50, from 4 to 25, from 4 to 10, from 4 to 8, from 8 to 300, from 8 to 200, from 8 to 150, from 8 to 100, from 8 to 75, from 8 to 50, from 8 to 25, from 8 to 10, from 10 to 300, from 10 to 200, from 10 to 150, from 10 to 100, from 10 to 75, from 10 to 50, from 10 to 25, from 25 to 300, from 25 to 200, from 25 to 150, from 25 to 100, from 25 to 75, from 25 to 50, from 50 to 300, from 50 to 200, from 50 to 150, from 50 to 100, from 50 to 75, from 75 to 300, from 75 to 200, from 75 to 150, from 75 to 100, from 100 to 300, from 100 to 200, from 100 to 150, from 150 to 300, from 150 to 200, or from 200 to 300 nucleotides of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of about 10, about 25, about 50, about 75, about 100, about 150, about 200, or about 300 nucleotides of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of about 200 nucleotides of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of 1, 2, 3, 4, 5, 6, 7, 8, or 10 nucleotides of the wild-type CAAT box-based promoter sequence. In certain embodiments, the modification included in the modified CAAT box-based promoter comprises a deletion of 9 nucleotides of the wild-type CAAT box-based promoter sequence.

**[0084]** The term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. A nucleic acid sequence is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For instance, a promoter or enhancer is operably linked to a gene if it affects the transcription of the gene. Operably linked nucleotide sequences are typically contiguous. However, as enhancers generally function when separated from the promoter by several kilobases and intronic sequences may be of variable lengths, some polynucleotide elements may be operably linked but not directly flanked and may even function *in trans* from a different allele or chromosome. In certain embodiments, a

gene (coding region) is operably linked to a modified TATA box- and/or modified CAAT box-based promoter.

**[0085]** The term “transgene” refers to an exogenous gene or polynucleotide sequence. The term “therapeutic transgene” refers to a transgene, which when replicated and/or expressed in or by the virus imparts a therapeutic effect in a target cell, body fluid, tissue, organ, physiological system, or subject.

**[0086]** In certain embodiments, the recombinant virus exhibits selective expression of a gene operably linked to a modified TATA box- and/or modified CAAT box-based promoter in a hyperproliferative and/or non-growth arrested cell, *e.g.*, a cancer cell, relative to a non-

hyperproliferative and/or growth arrested cell. In certain embodiments, the expression of the gene in the non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the expression of the gene in the hyperproliferative cell and/or non-growth arrested cell. In certain embodiments, the virus exhibits no detectable expression of the gene in a non-

hyperproliferative and/or growth arrested cell. In certain embodiments, the expression of a gene operably linked to a modified TATA box- and/or CAAT box-based promoter by the recombinant virus in a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the expression of the gene by a corresponding virus without the modified TATA

box- and/or CAAT box-based promoter. In certain embodiments, the recombinant virus exhibits selective expression of an early gene, *e.g.*, adenoviral E1a or E1b. Gene expression may be determined by any appropriate method known in the art, *e.g.*, Western blot as described in Example 2 herein.

**[0087]** In certain embodiments, the selective expression of a gene operably linked to a

modified TATA box- and/or CAAT box-based promoter, *e.g.*, an early gene, by the recombinant virus in a hyperproliferative and/or non-growth arrested cell, *e.g.*, a cancer cell, results in selective replication of the virus in the hyperproliferative and/or non-growth arrested cell. In certain embodiments, the replication of the virus in a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the replication of the virus in a hyperproliferative and/or non-growth arrested cell. In certain embodiments, the replication of

the virus in a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the replication of a corresponding virus without a modified TATA box- and/or CAAT box-based promoter. Viral replication may be determined by any appropriate method known in the art, *e.g.*, by assaying the expression of viral proteins, *e.g.*, by Western blot as described in Example 2 herein, by assaying viral mediated lysis, *e.g.*, by crystal violet staining as described in Example 3 herein, or by quantitative polymerase chain reaction (qPCR).

**[0088]** In certain embodiments, the selective expression of a gene operably linked to a modified TATA box- and/or CAAT box-based promoter, *e.g.*, an early gene, by the recombinant virus in a hyperproliferative and/or non-growth arrested cell, *e.g.*, a cancer cell, results in selective viral mediated lysis (*i.e.*, cytolytic activity) of the hyperproliferative and/or non-growth arrested cell. In certain embodiments, the viral mediated lysis of a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the viral mediated lysis of a hyperproliferative and/or non-growth arrested cell. In certain embodiments, the virus exhibits no detectable viral mediated lysis of a non-hyperproliferative and/or growth arrested cell. In certain embodiments, the viral mediated lysis of a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the viral mediated lysis of the cell by a corresponding virus without a modified TATA box- and/or CAAT box-based promoter. Viral mediated lysis may be determined by any appropriate method known in the art, *e.g.*, crystal violet staining as described in Example 3 herein.

**[0089]** In certain embodiments, the selective expression of a gene operably linked to a modified TATA box- and/or CAAT box-based promoter, *e.g.*, an early gene, by the recombinant virus in a hyperproliferative and/or non-growth arrested cell, *e.g.*, a cancer cell, results in selective expression of a therapeutic transgene by the recombinant virus. In certain embodiments, the expression of a therapeutic transgene in a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, or about 5% of the expression of the therapeutic transgene in the hyperproliferative and/or non-growth arrested cell. In certain embodiments, the virus exhibits no detectable expression of the therapeutic transgene in a non-hyperproliferative and/or growth arrested cell. In certain embodiments, the expression of a therapeutic transgene

in a non-hyperproliferative and/or growth arrested cell is about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10% , or about 5% of the expression of the therapeutic transgene in the cell by a corresponding virus without a modified TATA box- and/or CAAT box-based promoter. Therapeutic transgene expression may be 5 determined by any appropriate method known in the art, *e.g.*, ELISA as described in Example 4 herein.

**[0090]** The hyperproliferative and/or non-growth arrested cell may be a cancer cell, endothelial cell, epidermal cell, fibroblast, and/or immune cell. The hyperproliferative and/or non-growth arrested cell may be a cancer cell, *e.g.*, an anal cancer, basal cell carcinoma, 10 bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, gynecologic cancer, head and neck cancer, hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, 15 neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer or thyroid cancer cell. In further embodiments, the hyperproliferative cell is derived from a hyperproliferative disorder. Exemplary hyperproliferative disorders include blood vessel proliferation disorders 20 (*e.g.*, restenosis, retinopathies, and atherosclerosis), fibrotic disorders (*e.g.*, cirrhosis, *e.g.*, hepatic cirrhosis (which may be secondary to a viral infection such as hepatitis)), mesangial disorders (*e.g.*, human renal diseases, *e.g.*, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies), precancerous disorders (*e.g.*, hyperplasia or dysplasia), autoimmune 25 disorders, rheumatoid arthritis, psoriasis, lupus, idiopathic pulmonary fibrosis, sclerodermapulmonary hypertension, asthma, kidney fibrosis, COPD, cystic fibrosis, DIP, UIP, macular degeneration, hyperproliferative fibroblast disorders, and scleroderma.

**[0091]** Sequence identity may be determined in various ways that are within the skill in the art, *e.g.*, using publicly available computer software such as BLAST, BLAST-2, ALIGN or 30 Megalign (DNASTAR) software. BLAST (Basic Local Alignment Search Tool) analysis using the algorithm employed by the programs blastp, blastn, blastx, tblastn and tblastx (Karlin *et al.*, (1990) PROC. NATL. ACAD. SCI. USA 87:2264-2268; Altschul, (1993) J. MOL. EVOL. 36, 290-

300; Altschul *et al.*, (1997) NUCLEIC ACIDS RES. 25:3389-3402, incorporated by reference) are tailored for sequence similarity searching. For a discussion of basic issues in searching sequence databases see Altschul *et al.*, (1994) NATURE GENETICS 6:119-129, which is fully incorporated by reference. Those skilled in the art can determine appropriate parameters for

5 measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. The search parameters for histogram, descriptions, alignments, expect (*i.e.*, the statistical significance threshold for reporting matches against database sequences), cutoff, matrix and filter are at the default settings. The default scoring matrix used by blastp, blastx, tblastn, and tblastx is the BLOSUM62 matrix (Henikoff 10 *et al.*, (1992) PROC. NATL. ACAD. SCI. USA 89:10915-10919, fully incorporated by reference). Four blastn parameters may be adjusted as follows: Q=10 (gap creation penalty); R=10 (gap extension penalty); wink=1 (generates word hits at every wink.sup.th position along the query); and gapw=16 (sets the window width within which gapped alignments are generated). The equivalent Blastp parameter settings may be Q=9; R=2; wink=1; and gapw=32. Searches may 15 also be conducted using the NCBI (National Center for Biotechnology Information) BLAST Advanced Option parameter (e.g.: -G, Cost to open gap [Integer]: default = 5 for nucleotides/ 11 for proteins; -E, Cost to extend gap [Integer]: default = 2 for nucleotides/ 1 for proteins; -q, Penalty for nucleotide mismatch [Integer]: default = -3; -r, reward for nucleotide match [Integer]: default = 1; -e, expect value [Real]: default = 10; -W, wordsize [Integer]: default = 11 20 for nucleotides/ 28 for megablast/ 3 for proteins; -y, Dropoff (X) for blast extensions in bits: default = 20 for blastn/ 7 for others; -X, X dropoff value for gapped alignment (in bits): default = 15 for all programs, not applicable to blastn; and -Z, final X dropoff value for gapped alignment (in bits): 50 for blastn, 25 for others). ClustalW for pairwise protein alignments may also be used (default parameters may include, *e.g.*, Blosum62 matrix and Gap Opening Penalty 25 = 10 and Gap Extension Penalty = 0.1). A Bestfit comparison between sequences, available in the GCG package version 10.0, uses DNA parameters GAP=50 (gap creation penalty) and LEN=3 (gap extension penalty) and the equivalent settings in protein comparisons are GAP=8 and LEN=2.

30 **I. Viruses**

[0092] The term "virus" is used herein to refer any of the obligate intracellular parasites having no protein-synthesizing or energy-generating mechanism. The viral genome may be

RNA or DNA. The viruses useful in the practice of the present invention include recombinantly modified enveloped or non-enveloped DNA and RNA viruses, preferably selected from baculoviridae, parvoviridae, picornoviridae, herpesviridae, poxyviridae, or adenoviridae. A recombinantly modified virus is referred to herein as a "recombinant virus."

5 A recombinant virus may, *e.g.*, be modified by recombinant DNA techniques to be replication deficient, conditionally replicating, or replication competent, and/or be modified by recombinant DNA techniques to include expression of exogenous transgenes. Chimeric viral vectors which exploit advantageous elements of each of the parent vector properties (See, *e.g.*, Feng *et al.* (1997) NATURE BIOTECHNOLOGY 15:866-870) may also be useful in the practice of  
10 the present invention. Although it is generally favored to employ a virus from the species to be treated, in certain instances it may be advantageous to use vectors derived from different species that possess favorable pathogenic features. For example, equine herpes virus vectors for human gene therapy are described in PCT Publication No. WO 98/27216. The vectors are described as useful for the treatment of humans as the equine virus is not pathogenic to  
15 humans. Similarly, ovine adenoviral vectors may be used in human gene therapy as they are claimed to avoid the antibodies against the human adenoviral vectors. Such vectors are described in PCT Publication No. WO 97/06826.

**[0093]** Viruses useful for the practice of the invention contain a TATA box- and/or CAAT box-based promoter. In certain embodiments, the TATA box- and/or CAAT box-based promoter is the promoter for an early phase gene, *e.g.*, a gene encoding a protein that is produced following entry into the host cell but prior to replication, which typically initiates replication of the genome and expression of late genes.

20 **[0094]** Examples of viruses with early gene TATA box- and/or CAAT box-based promoters include Human immunodeficiency virus-1 (HIV-1), herpes simplex virus type 1, adeno-associated virus, Influenza virus, reovirus, vesicular stomatitis virus (VSV), newcastle virus, vaccinia virus, poliovirus, measles virus, mumps virus, sindbis virus (SIN), and sendai virus (SV).

25 **[0095]** Preferably, the recombinant virus is an adenovirus. Adenoviruses are medium-sized (90-100 nm), non-enveloped (naked), icosahedral viruses composed of a nucleocapsid and a double-stranded linear DNA genome. Adenoviruses replicate in the nucleus of mammalian cells using the host's replication machinery. The term "adenovirus" refers to any virus in the

genus Adenoviridae including, but not limited to, human, bovine, ovine, equine, canine, porcine, murine, and simian adenovirus subgenera. In particular, human adenoviruses includes the A-F subgenera as well as the individual serotypes thereof, the individual serotypes and A-F subgenera including but not limited to human adenovirus types 1, 2, 3, 4, 4a, 5, 6, 7, 8, 9, 10,

5 11 (Ad11a and Ad11p), 12, 13, 14, 15, 16, 17, 18, 19, 19a, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34a, 35, 35p, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, and 91.

Preferred are recombinant viruses derived from human adenovirus types 2, 5, and 35. Unless stated otherwise, all adenovirus type 5 nucleotide numbers are relative to the NCBI reference sequence AC\_000008.1, which is depicted herein in SEQ ID NO: 8, and all adenovirus type 35 nucleotide numbers are relative to the NCBI reference sequence AC\_000019.1, which is depicted herein in SEQ ID NO: 24. The sequence of an exemplary vector plasmid that encodes the 5' end of the adenovirus type 5 genome (pXC1) is depicted herein in SEQ ID NO: 2.

**[0096]** The adenovirus replication cycle has two phases: an early phase, during which four transcription units E1, E2, E3, and E4 are expressed, and a late phase which occurs after the onset of viral DNA synthesis when late transcripts are expressed primarily from the major late promoter (MLP). The late messages encode most of the virus's structural proteins. The gene products of E1, E2 and E4 are responsible for transcriptional activation, cell transformation, viral DNA replication, as well as other viral functions, and are necessary for viral growth.

**[0097]** In certain embodiments, the modified TATA box-based promoter is an adenoviral E1a, E1b or E4 promoter. In a certain embodiments, the modified TATA box-based promoter is an adenoviral E1a promoter, *e.g.*, the Ad5 E1a promoter. The modification included in the modified TATA box-based promoter may, *e.g.*, comprise a deletion of the entire E1a promoter TATA box, *e.g.*, comprise a deletion corresponding to nucleotides -27 to -24 of the Ad5 E1a promoter. In certain embodiments, the virus comprises a deletion of nucleotides corresponding to -27 to -24, -31 to -24, -44 to +54, or -146 to +54 of the Ad5 E1a promoter, which correspond, respectively, to nucleotides 471 to 474, 467 to 474, 454 to 551 and 352 to 551 of SEQ ID NO: 2, and to nucleotides 472 to 475, 468 to 475, 455 to 552, and 353 to 552 of SEQ ID NO: 8. In certain embodiments, the virus comprises a deletion of nucleotides corresponding to -29 to -26, -33 to -26, -44 to +52, or -148 to +52 of the Ad5 E1a promoter.

20 30 **[0098]** In certain embodiments, the virus comprises a deletion of nucleotides corresponding to about -50 to about -10, about -50 to about -20, about -50 to about -30, about -50 to about -40,

about -40 to about -10, about -40 to about -20, about -40 to about -30, about -30 to about -10, about -30 to about -20, or about -20 to about -10 of the Ad5 E1a promoter.

**[0099]** In certain embodiments, the virus comprises a polynucleotide deletion that results in virus comprising the sequence CTAGGACTG (SEQ ID NO: 7), AGTGCCCG (SEQ ID NO:

5 12), or TATTCCCG (SEQ ID NO: 13), which result from joining the two polynucleotide sequences that would otherwise flank the deleted polynucleotide sequence. In certain embodiments, the virus comprises the sequence CTAGGACTG (SEQ ID NO: 7), AGTGCCCG (SEQ ID NO: 12), or TATTCCCG (SEQ ID NO: 13) or a sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity 10 to CTAGGACTG (SEQ ID NO: 7), AGTGCCCG (SEQ ID NO: 12), or TATTCCCG (SEQ ID NO: 13)

**[00100]** In certain embodiments, the modified CAAT box-based promoter is an adenoviral E1a, E1b or E4 promoter. In a certain embodiments, the modified CAAT box-based promoter is an adenoviral E1a promoter, *e.g.*, the Ad5 E1a promoter. The modification included in the 15 modified CAAT box-based promoter may, *e.g.*, comprise a deletion of the entire E1a promoter CAAT box, *e.g.*, comprise a deletion corresponding to nucleotides -76 to -68 of the adenovirus type 5 E1a promoter, which corresponds to nucleotides 422 to 430 of SEQ ID NO: 2, and to nucleotides 423 to 431 of SEQ ID NO: 8.

**[00101]** In certain embodiments, the virus comprises a deletion of nucleotides corresponding 20 to about -90 to about -50, about -90 to about -60, about -90 to about -70, about -90 to about -80, about -80 to about -50, about -80 to about -60, about -80 to about -70, about -70 to about -50, about -70 to about -60, or about -60 to about -50, of the Ad5 E1a promoter.

**[00102]** In certain embodiments, the virus comprises a polynucleotide deletion that results in virus comprising the sequence TTCCGTGGCG (SEQ ID NO: 14), which results from joining 25 the two polynucleotide sequences that would otherwise flank the deleted polynucleotide sequence. In certain embodiments, the virus comprises the sequence TTCCGTGGCG (SEQ ID NO: 14) or a sequence having 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to TTCCGTGGCG (SEQ ID NO: 14).

**[00103]** In certain embodiments, the virus comprises a deletion of nucleotides corresponding 30 to about -200 to about +50, about -175 to about +50, about -150 to about +50, about -125 about +50, about -100 to about +50, about -75 to about +50, about -50 to about +50, about -25 to

about +50, about +1 to about +50, about +25 to about +50, about -200 to about +25, about -175 to about +25, about -150 to about +25, about -125 about +25, about -100 to about +25, about -75 to about +25, about -50 to about +25, about -25 to about +25, about +1 to about +25, about -200 to about +1, about -175 to about +1, about -150 to about +1, about -125 about +1, about 5 -100 to about +1, about -75 to about +1, about -50 to about +1, about -25 to about +1, about -200 to about -25, about -175 to about -25, about -150 to about -25, about -125 about -25, about -100 to about -25, about -75 to about -25, about -50 to about -25, about -200 to about -50, about -175 to about -50, about -150 to about -50, about -125 about -50, about -100 to about -50, about -75 to about -50, about -200 to about -75, about -175 to about -75, about -150 to about -75, about -125 about -75, about -100 to about -75, about -75 to about -75, about -100 to about -100, about -175 to about -100, about -150 to about -100, about -125 about -100, about -200 to about -125, about -175 to about -125, about -150 to about -125, about -200 to about -150, about -175 to about -150, or 10 about -200 to about -175 of the Ad5 E1a promoter.

15 [00104] In certain embodiments, in addition to a modified TATA box- and/or CAAT box-based promoter, the virus has one or more additional modifications to a regulatory sequence or promoter. An additional modification to a regulatory sequence or promoter comprises a deletion, substitution, or addition of one or more nucleotides compared to the wild-type sequence of the regulatory sequence or promoter. The additional modification may be adjacent to, or distal from, the modified TATA box- and/or CAAT box-based promoter.

20 [00105] In certain embodiments, the additional modification of a regulatory sequence or promoter comprises a modification of sequence of a transcription factor binding site to reduce affinity for the transcription factor, for example, by deleting a portion thereof, or by inserting a single point mutation into the binding site. In certain embodiments, the additional modified regulatory sequence enhances expression in cancer cells, but attenuates expression in normal 25 cells.

30 [00106] In certain embodiments, the additional modification of a regulatory sequence or promoter comprises an additional modification to an E1a regulatory sequence. The E1a regulatory sequence contains five binding sites for the transcription factor Pea3, designated Pea3 I, Pea3 II, Pea3 III, Pea3 IV, and Pea3 V, where Pea3 I is the Pea3 binding site most proximal to the E1a start site, and Pea3 V is most distal. The E1a regulatory sequence also contains binding sites for the transcription factor E2F, hereby designated E2F I and E2F II,

where E2F I is the E2F binding site most proximal to the E1a start site, and E2F II is more distal. From the E1a start site, the binding sites are arranged: Pea3 I, E2F I, Pea3 II, E2F II, Pea3 III, Pea3 IV, and Pea3 V.

**[00107]** In certain embodiments, at least one of these seven binding sites, or a functional

5 portion thereof, is deleted. A "functional portion" is a portion of the binding site that, when deleted, decreases or even eliminates the functionality, *e.g.* binding affinity, of the binding site to its respective transcription factor (Pea3 or E2F) by, for example, at least 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% relative to the complete sequence. In certain embodiments, one or more entire binding sites are deleted. In certain embodiments, a functional portion of one or 10 more binding sites is deleted. A "deleted binding site" encompasses both the deletion of an entire binding site and the deletion of a functional portion. When two or more binding sites are deleted, any combination of entire binding site deletion and functional portion deletion may be used.

**[00108]** In certain embodiments, at least one Pea3 binding site, or a functional portion

15 thereof, is deleted. The deleted Pea3 binding site can be Pea3 I, Pea3 II, Pea3 III, Pea3 IV, and/or Pea3 V. In certain embodiments, the deleted Pea3 binding site is Pea3 II, Pea3 III, Pea3 IV, and/or Pea3 V. In certain embodiments, the deleted Pea3 binding site is Pea3 IV and/or Pea3 V. In certain embodiments, the deleted Pea3 binding site is Pea3 II and/or Pea3 III. In certain embodiments, the deleted Pea3 binding site is both Pea3 II and Pea3 III. In certain 20 embodiments, the Pea3 I binding site, or a functional portion thereof, is retained.

**[00109]** In certain embodiments, at least one E2F binding site, or a functional portion

thereof, is deleted. In certain embodiments, at least one E2F binding site, or a functional portion thereof, is retained. In certain embodiments, the retained E2F binding site is E2F I and/or E2F II. In certain embodiments, the retained E2F binding site is E2F II. In certain 25 embodiments, the total deletion consists essentially of one or more of Pea3 II, Pea3 III, Pea3 IV, and/or Pea3 V, or functional portions thereof. In certain embodiments, the virus has a deletion of a 50 base pair region located from -305 to -255 upstream of the E1a initiation site, hereafter referred to as the TAV-255 deletion. In certain embodiments, the virus has a deletion of a 50 base pair region located from -304 to -255 upstream of the E1a initiation site, *e.g.*, 30 corresponding to 195-244 of the Ad5 genome (SEQ ID NO: 8), hereafter referred to as the

TAV-255 deletion. In certain embodiments, the TAV-255 deletion results in an E1a promoter that comprises the sequence GGTGTTTG (SEQ ID NO: 11).

**[00110]** A disclosed recombinant virus may comprise a nucleotide sequence that encodes for a therapeutic transgene. The therapeutic transgene may encode a therapeutic nucleic acid, *e.g.*,

5 an antisense RNA or ribozyme RNA. The therapeutic transgene may encode a therapeutic peptide or polypeptide, *e.g.*, an apoptotic agent, antibody, CTL responsive peptide, cytokine, cytolytic agent, cytotoxic agent, enzyme, heterologous antigen expressed on the surface of a tumor cell to elicit an immune response, immunostimulatory or immunomodulatory agent, interferon, lytic peptide, oncoprotein, polypeptide which catalyzes processes leading to cell

10 death, polypeptide which complements genetic defects in somatic cells, tumor suppressor protein, vaccine antigen, or any combination thereof.

**[00111]** In certain embodiments, the therapeutic transgene encodes a therapeutic polypeptide selected from acetylcholine, an anti-PD-1 antibody heavy chain or light chain, an anti-PD-L1 antibody heavy chain or light chain, BORIS/CTCFL, CD19, CD20, CD80, CD86, CD137L,

15 CD154, DKK1/Wnt, ICAM-1, IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-17, IL-23, IL-23A/p19, interferon-gamma, TGF- $\beta$ , a TGF- $\beta$  trap, FGF, IL-24, IL-27, IL-35, MAGE, NY-ESO-1, p53, and thymidine kinase. In certain embodiments, the therapeutic transgene is a TGF- $\beta$  trap. TGF- $\beta$  trap proteins suitable for use in the invention are described in United States Patent Application No. 15/717,199, filed September 27, 2017.

20 **[00112]** The adenoviral E1b-19k gene functions primarily as an anti-apoptotic gene and is a homolog of the cellular anti-apoptotic gene, BCL-2. Since host cell death prior to maturation of the progeny viral particles would restrict viral replication, E1b-19k is expressed as part of the E1 cassette to prevent premature cell death thereby allowing the infection to proceed and yield mature virions. Accordingly, in certain embodiments, a recombinant virus is provided that

25 includes an E1b-19K insertion site, *e.g.*, the adenovirus has a nucleotide sequence encoding a therapeutic transgene inserted into an E1b-19K insertion site.

**[00113]** In certain embodiments, the E1b-19K insertion site is located between the start site of E1b-19K (*i.e.*, the nucleotide sequence encoding the start codon of E1b-19k, *e.g.*,

30 corresponding to nucleotides 1714-1716 of SEQ ID NO: 8) and the start site of E1b-55K (*i.e.*, the nucleotide sequence encoding the start codon of E1b-55k, *e.g.*, corresponding to nucleotides 2019-2021 of SEQ ID NO: 8). Throughout the description and claims, an insertion between

two sites, for example, an insertion between (i) a start site of a first gene (*e.g.*, E1b-19k) and a start site of a second gene, (*e.g.*, E1b-55K), (ii) a start site of a first gene and a stop site of a second gene, (iii) a stop site of a first gene and start site of a second gene, or (iv) a stop site of first gene and a stop site of a second gene, is understood to mean that all or a portion of the

5 nucleotides constituting a given start site or a stop site surrounding the insertion may be present or absent in the final virus. Similarly, an insertion between two nucleotides is understood to mean that the nucleotides surrounding the insertion may be present or absent in the final virus.

**[00114]** In certain embodiments, the E1b-19K insertion site is located between the start site of E1b-19K (*i.e.*, the nucleotide sequence encoding the start codon of E1b-19k, *e.g.*,

10 corresponding to nucleotides 1714-1716 of SEQ ID NO: 8) and the stop site of E1b-19K (*i.e.*, the nucleotide sequence encoding the stop codon of E1b-19k, *e.g.*, corresponding to nucleotides 2242-2244 of SEQ ID NO: 8). In certain embodiments, the E1b-19K insertion site comprises a deletion of from about 100 to about 305, about 100 to about 300, about 100 to about 250, about 100 to about 200, about 100 to about 150, about 150 to about 305, about 150 to about 300,

15 about 150 to about 250, or about 150 to about 200 nucleotides adjacent the start site of E1b-19K. In certain embodiments, the E1b-19K insertion site comprises a deletion of about 200 nucleotides, *e.g.*, 203 nucleotides adjacent the start site of E1b-19K. In certain embodiments,

the E1b-19K insertion site comprises a deletion corresponding to nucleotides 1714-1916 of the Ad5 genome (SEQ ID NO: 8), or the nucleotide sequence encoding the therapeutic transgene is

20 inserted between nucleotides corresponding to 1714 and 1916 of the Ad5 genome (SEQ ID NO: 8). In certain embodiments, the nucleotide sequence encoding the therapeutic transgene is

inserted between CTGACCTC (SEQ ID NO: 9) and TCACCAGG (SEQ ID NO: 10), *e.g.*, the recombinant adenovirus comprises, in a 5' to 3' orientation, CTGACCTC (SEQ ID NO: 9), the nucleotide sequence encoding the therapeutic transgene, and TCACCAGG (SEQ ID NO: 10).

25 CTGACCTC (SEQ ID NO: 9) and TCACCAGG (SEQ ID NO: 10) define unique boundary sequences for the E1b-19K insertion site within the Ad5 genome (SEQ ID NO: 8). Throughout the description and claims, a deletion adjacent to a site, for example, a deletion adjacent to a start site of a gene or a deletion adjacent to a stop site of a gene, is understood to mean that the deletion may include a deletion of all, a portion, or none of the nucleotides constituting a given

30 start site or a stop site.

**[00115]** In certain embodiments, in any of the foregoing viruses, the recombinant adenovirus further comprises an E4 deletion. In certain embodiments, the E4 deletion is located between

the start site of E4-ORF6/7 (*i.e.*, the nucleotide sequence encoding the start codon of E4-ORF6/7, *e.g.*, corresponding to nucleotides 34075-34077 of SEQ ID NO: 23) and the right inverted terminal repeat (ITR; *e.g.*, corresponding to nucleotides 35836-35938 of SEQ ID NO: 23). In certain embodiments, the E4 deletion is located between the start site of E4-ORF6/7 and

5 the start site of E4-ORF1 (*i.e.*, the nucleotide sequence encoding the start codon of E4-ORF1, *e.g.*, corresponding to nucleotides 35524-35526 of SEQ ID NO: 23). In certain embodiments, the E4 deletion comprises a deletion of a nucleotide sequence between the start site of E4-ORF6/7 and the start site of E4-ORF1. In certain embodiments, the E4 deletion comprises a deletion of from about 500 to about 2500, from about 500 to about 2000, from about 500 to

10 about 1500, from about 500 to about 1000, from about 1000 to about 2500, from about 1000 to about 2000, from about 1000 to about 1500, from about 1500 to about 2500, from about 1500 to about 2000, or from about 2000 to about 2500 nucleotides. In certain embodiments, the E4 deletion comprises a deletion of from about 250 to about 1500, from about 250 to about 1250, from about 250 to about 1000, from about 250 to about 750, from about 250 to about 500, from

15 500 to about 1500, from about 500 to about 1250, from about 500 to about 1000, from about 500 to about 750, from 750 to about 1500, from about 750 to about 1250, from about 750 to about 1000, from about 1000 to about 1500, or from about 1000 to about 1250 nucleotides adjacent the start site of E4-ORF6/7. In certain embodiments, the E4 deletion comprises a deletion of about 1450 nucleotides adjacent the start site of E4-ORF6/7, *e.g.*, the E4 deletion

20 comprises a deletion of about 1449 nucleotides adjacent the start site of E4-ORF6/7. In certain embodiments, the E4 deletion comprises a deletion corresponding to nucleotides 34078-35526 of the Ad5 genome (SEQ ID NO: 23).

## **II. Methods of Viral Production**

25 [00116] Methods for producing recombinant viruses of the invention are known in the art. Typically, a disclosed virus is produced in a suitable host cell line using conventional techniques including culturing a transfected or infected host cell under suitable conditions so as to allow the production of infectious viral particles. Nucleic acids encoding viral genes can be incorporated into plasmids and introduced into host cells through conventional transfection or

30 transformation techniques. Exemplary suitable host cells for production of disclosed viruses include human cell lines such as HeLa, Hela-S3, HEK293, 911, A549, HER96, or PER-C6 cells. Specific production and purification conditions will vary depending upon the virus and

the production system employed. For adenovirus, the traditional method for the generation of viral particles is co-transfection followed by subsequent *in vivo* recombination of a shuttle plasmid (usually containing a small subset of the adenoviral genome and optionally containing a potential transgene an expression cassette) and an adenoviral helper plasmid (containing most 5 of the entire adenoviral genome).

**[00117]** Alternative technologies for the generation of adenovirus include utilization of the bacterial artificial chromosome (BAC) system, *in vivo* bacterial recombination in a *recA*<sup>+</sup> bacterial strain utilizing two plasmids containing complementary adenoviral sequences, and the yeast artificial chromosome (YAC) system.

10 **[00118]** Following production, infectious viral particles are recovered from the culture and optionally purified. Typical purification steps may include plaque purification, centrifugation, *e.g.*, cesium chloride gradient centrifugation, clarification, enzymatic treatment, *e.g.*, benzonase or protease treatment, chromatographic steps, *e.g.*, ion exchange chromatography or filtration steps.

15

### **III. Therapeutic Compositions and Methods of Treatment**

20 **[00119]** For therapeutic use, a recombinant virus is preferably is combined with a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” means buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. The carrier(s) should be “acceptable” in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient. Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are 25 compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art.

**[00120]** Pharmaceutical compositions containing recombinant viruses disclosed herein can be presented in a dosage unit form and can be prepared by any suitable method. A pharmaceutical composition should be formulated to be compatible with its intended route of 30 administration. Examples of routes of administration are intravenous (IV), intradermal, inhalation, transdermal, topical, transmucosal, and rectal administration. A preferred route of

administration for fusion proteins is IV infusion. Useful formulations can be prepared by methods known in the pharmaceutical art. For example, see *Remington's Pharmaceutical Sciences*, 18th ed. (Mack Publishing Company, 1990). Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution,

5 fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.

**[00121]** For intravenous administration, suitable carriers include physiological saline,

10 bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). The carrier should be stable under the conditions of manufacture and storage, and should be preserved against microorganisms. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethyleneglycol), and suitable mixtures thereof.

15 **[00122]** Pharmaceutical formulations preferably are sterile. Sterilization can be accomplished by any suitable method, *e.g.*, filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.

**[00123]** The term "effective amount" as used herein refers to the amount of an active

20 component (*e.g.*, the amount of a recombinant virus of the present invention) sufficient to effect beneficial or desired results. An effective amount can be administered in one or more administrations, applications or dosages and is not intended to be limited to a particular formulation or administration route.

**[00124]** In certain embodiments, a therapeutically effective amount of active component is

25 in the range of 0.1 mg/kg to 100 mg/kg, *e.g.*, 1 mg/kg to 100 mg/kg, 1 mg/kg to 10 mg/kg. In certain embodiments, a therapeutically effective amount of a recombinant virus is in the range of  $10^2$  to  $10^{15}$  plaque forming units (pfus), *e.g.*,  $10^2$  to  $10^{10}$ ,  $10^2$  to  $10^5$ ,  $10^5$  to  $10^{15}$ ,  $10^5$  to  $10^{10}$ , or  $10^{10}$  to  $10^{15}$  plaque forming units. The amount administered will depend on variables such as the type and extent of disease or indication to be treated, the overall health of the patient, the *in* 30 *vivo* potency of the antibody, the pharmaceutical formulation, and the route of administration. The initial dosage can be increased beyond the upper level in order to rapidly

achieve the desired blood-level or tissue-level. Alternatively, the initial dosage can be smaller than the optimum, and the daily dosage may be progressively increased during the course of treatment. Human dosage can be optimized, *e.g.*, in a conventional Phase I dose escalation study designed to run from 0.5 mg/kg to 20 mg/kg. Dosing frequency can vary, depending on

5 factors such as route of administration, dosage amount, serum half-life of the virus, and the disease being treated. Exemplary dosing frequencies are once per day, once per week and once every two weeks. A preferred route of administration is parenteral, *e.g.*, intravenous infusion. Formulation of virus -based drugs is within ordinary skill in the art. In certain embodiments, a recombinant virus is lyophilized, and then reconstituted in buffered saline, at the time of  
10 administration.

**[00125]** The recombinant viruses disclosed herein can be used to treat various medical indications. For example, the recombinant viruses can be used to treat various hyperproliferative diseases, *e.g.*, cancers. The hyperproliferative cells, *e.g.*, cancer cells, are exposed to a therapeutically effective amount of the recombinant virus so as to inhibit or reduce  
15 proliferation of the cancer cells. The invention provides a method of treating a cancer in a subject. The method comprises administering to the subject an effective amount of a recombinant virus of the invention either alone or in a combination with another therapeutic agent to treat the cancer in the subject. In certain embodiments, administering an effective amount of a recombinant virus to a subject reduces tumor load in that subject by at least 30%,  
20 at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%.

**[00126]** As used herein, “treat”, “treating” and “treatment” mean the treatment of a disease in a subject, *e.g.*, in a human. This includes: (a) inhibiting the disease, *i.e.*, arresting its development; and (b) relieving the disease, *i.e.*, causing regression of the disease state. As used herein, the terms “subject” and “patient” refer to an organism to be treated by the methods and  
25 compositions described herein. Such organisms preferably include, but are not limited to, mammals (*e.g.*, murines, simians, equines, bovines, porcines, canines, felines, and the like), and more preferably includes humans.

**[00127]** Examples of cancers include solid tumors, soft tissue tumors, hematopoietic tumors and metastatic lesions. Examples of hematopoietic tumors include, leukemia, acute leukemia,  
30 acute lymphoblastic leukemia (ALL), B-cell, T-cell or FAB ALL, acute myeloid leukemia (AML), chronic myelocytic leukemia (CML), chronic lymphocytic leukemia (CLL), *e.g.*,

transformed CLL, diffuse large B-cell lymphomas (DLBCL), follicular lymphoma, hairy cell leukemia, myelodysplastic syndrome (MDS), a lymphoma, Hodgkin's disease, a malignant lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, or Richter's Syndrome (Richter's Transformation). Examples of solid tumors include malignancies, *e.g.*,

5      sarcomas, adenocarcinomas, and carcinomas, of the various organ systems, such as those affecting head and neck (including pharynx), thyroid, lung (small cell or non-small cell lung carcinoma (NSCLC)), breast, lymphoid, gastrointestinal (*e.g.*, oral, esophageal, stomach, liver, pancreas, small intestine, colon and rectum, anal canal), genitals and genitourinary tract (*e.g.*, renal, urothelial, bladder, ovarian, uterine, cervical, endometrial, prostate, testicular), CNS  
10     (*e.g.*, neural or glial cells, *e.g.*, neuroblastoma or glioma), or skin (*e.g.*, melanoma).

**[00128]** In certain embodiments, the cancer is selected from anal cancer, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, 15     hepatocellular carcinoma, gynecologic cancer, head and neck cancer, hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer 20     and thyroid cancer.

**[00129]** Additional exemplary hyperproliferative diseases include blood vessel proliferation disorders (*e.g.*, restenosis, retinopathies, and atherosclerosis), fibrotic disorders (*e.g.*, cirrhosis, *e.g.*, hepatic cirrhosis (which may be secondary to a viral infection such as hepatitis)), mesangial disorders (*e.g.*, human renal diseases, *e.g.*, glomerulonephritis, diabetic nephropathy, 25     malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies), precancerous disorders (*e.g.*, hyperplasia or dysplasia), autoimmune disorders, rheumatoid arthritis, psoriasis, lupus, idiopathic pulmonary fibrosis, sclerodermapulmonary hypertension, asthma, kidney fibrosis, COPD, cystic fibrosis, DIP, UIP, macular degeneration, hyperproliferative fibroblast disorders, and scleroderma.

**[00130]** In certain embodiments, a recombinant virus is administered to the subject in combination with one or more therapies, *e.g.*, surgery, radiation, chemotherapy, immunotherapy, hormone therapy, or virotherapy.

5 **[00131]** In certain embodiments, a recombinant virus of the invention is administered in combination with a tyrosine kinase inhibitor, *e.g.*, erlotinib.

10 **[00132]** In certain embodiments, a recombinant virus of the invention is administered in combination with a checkpoint inhibitor, *e.g.*, an anti-CTLA-4 antibody, an anti-PD-1 antibody, or an anti-PD-L1 antibody. Exemplary anti-PD-1 antibodies include, for example, nivolumab (Opdivo®, Bristol-Myers Squibb Co.), pembrolizumab (Keytruda®, Merck Sharp & Dohme Corp.), PDR001 (Novartis Pharmaceuticals), and pidilizumab (CT-011, Cure Tech). Exemplary anti-PD-L1 antibodies include, for example, atezolizumab (Tecentriq®, Genentech), duvalumab (AstraZeneca), MEDI4736, avelumab, and BMS 936559 (Bristol Myers Squibb Co.).

15 **[00133]** The term administered "in combination," as used herein, is understood to mean that two (or more) different treatments are delivered to the subject during the course of the subject's affliction with the disorder, such that the effects of the treatments on the patient overlap at a point in time. In certain embodiments, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap in terms of administration. This is sometimes referred to herein as "simultaneous" or "concurrent delivery." In other 20 embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. In some embodiments of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, *e.g.*, an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in 25 the absence of the first treatment, or the analogous situation is seen with the first treatment. In certain embodiments, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment 30 delivered is still detectable when the second is delivered.

**[00134]** In certain embodiments, the effective amount of the recombinant virus is identified by measuring an immune response to an antigen in the subject and/or the method of treating the subject further comprises measuring an immune response to an antigen in the subject.

Hyperproliferative diseases, *e.g.*, cancers, may be characterized by immunosuppression, and

5 measuring an immune response to an antigen in the subject may be indicative of the level of immunosuppression in the subject. Accordingly, measuring an immune response to an antigen in the subject may be indicative of the efficacy of the treatment and/or the effective amount of the recombinant virus. The immune response to the antigen in the subject may be measured by any method known in the art. In certain embodiments, the immune response to the antigen is  
10 measured by injecting the subject with the antigen at an injection site on the skin of the subject and measuring the size of an induration or amount of inflammation at the injection site. In certain embodiments, the immune response to the antigen is measured by release of a cytokine from a cell of the subject (*e.g.*, interferon gamma, IL-4 and/or IL-5) upon exposure to the antigen.

15 **[00135]** Throughout the description, where viruses, compositions, and systems are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions, devices, and systems of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods  
20 according to the present invention that consist essentially of, or consist of, the recited processing steps.

**[00136]** In the application, where an element or component is said to be included in and/or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components, or the element or

25 component can be selected from a group consisting of two or more of the recited elements or components.

**[00137]** Further, it should be understood that elements and/or features of a virus, a composition, a system, a method, or a process described herein can be combined in a variety of ways without departing from the spirit and scope of the present invention, whether explicit or  
30 implicit herein. For example, where reference is made to a particular compound, that compound can be used in various embodiments of compositions of the present invention and/or

in methods of the present invention, unless otherwise understood from the context. In other words, within this application, embodiments have been described and depicted in a way that enables a clear and concise application to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from 5 the present teachings and invention(s). For example, it will be appreciated that all features described and depicted herein can be applicable to all aspects of the invention(s) described and depicted herein.

10 [00138] It should be understood that the expression “at least one of” includes individually each of the recited objects after the expression and the various combinations of two or more of the recited objects unless otherwise understood from the context and use. The expression “and/or” in connection with three or more recited objects should be understood to have the same meaning unless otherwise understood from the context.

15 [00139] The use of the term “include,” “includes,” “including,” “have,” “has,” “having,” “contain,” “contains,” or “containing,” including grammatical equivalents thereof, should be understood generally as open-ended and non-limiting, for example, not excluding additional unrecited elements or steps, unless otherwise specifically stated or understood from the context.

20 [00140] At various places in the present specification, viruses, compositions, systems, processes and methods, or features thereof, are disclosed in groups or in ranges. It is specifically intended that the description include each and every individual subcombination of the members of such groups and ranges. By way of other examples, an integer in the range of 1 to 20 is specifically intended to individually disclose 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20.

25 [00141] Where the use of the term “about” is before a quantitative value, the present invention also includes the specific quantitative value itself, unless specifically stated otherwise. As used herein, the term “about” refers to a  $\pm 10\%$  variation from the nominal value unless otherwise indicated or inferred.

[00142] It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present invention remain operable. Moreover, two or more steps or actions may be conducted simultaneously.

[00143] The use of any and all examples, or exemplary language herein, for example, “such as” or “including,” is intended merely to illustrate better the present invention and does not pose a limitation on the scope of the invention unless claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the 5 present invention.

## EXAMPLES

[00144] The following Examples are merely illustrative and are not intended to limit the scope or content of the invention in any way.

### Example 1: Plasmid and Adenovirus Construction

10 [00145] This Example describes the production of recombinant type 5 (Ad5) adenoviruses with deletions in the E1a promoter region that include a TATA and/or a CAAT box.

15 [00146] The adenoviral vector plasmid pXC1, which carries the 5' portion of the Ad5 genome, was acquired from Microbix Biosystem (Toronto, Canada). The nucleotide sequence of the pXC1 vector plasmid is depicted herein in SEQ ID NO: 2. The Ad5 genome NCBI reference sequence AC\_000008.1 is depicted herein in SEQ ID NO: 8. **FIG. 1F** depicts the nucleotide sequence of the 5' end of wild-type Ad5 up to the start codon of the E1a gene indicating the location of the CAAT box and TATA box.

20 [00147] A modified pXC1 vector plasmid was generated that had a deletion of 200 nucleotides corresponding to nucleotides 352-551 of SEQ ID NO: 2 (which correspond to nucleotides 353-552 of SEQ ID NO: 8), which included the CAAT box and the TATA box in the E1a promoter. The mutated vector plasmid is hereafter referred to as pXC1-Δ350, and any resulting viral particles produced therefrom are hereafter referred to as Ad-Δ350. The nucleotide sequence of the 5' end of pXC1-Δ350, up to the start codon of the E1a gene, is shown in SEQ ID NO: 20. The full length nucleotide sequence of pXC1-Δ350 is shown in SEQ 25 ID NO: 4. The nucleotide sequence of the 5' end of Ad-Δ350, up to the start codon of the E1a gene, is shown in **FIG. 1A** and SEQ ID NO: 3. The twenty-one nucleotides at the 5' terminus of the pXC1 vector plasmid (and any modified pXC1 vector plasmids) differ from the wild-type adenoviral sequence, however, these nucleotides are converted to the wild-type adenoviral sequence during the process of generating a recombinant adenovirus.

**[00148]** Where indicated, pXC1-Δ350 was further modified to carry a SalI site at the start site of the E1b-19k region and an XhoI site 200 base pairs 3' of the SalI site to facilitate insertion of therapeutic transgenes. The nucleotide sequence of the modified E1b-19k region is given in SEQ ID NO: 5. The resulting vector plasmid is hereafter referred to as pXC1-Δ350-Δ19k, and any resulting viral particles produced therefrom are hereafter referred to as Ad-Δ350-Δ19k.

5

**[00149]** Where indicated, the gene for murine GM-CSF was cloned into pXC1-Δ350-Δ19k in the modified E1b-19k region between the SalI and XhoI sites. The amino acid sequence for mouse GM-CSF is given in SEQ ID NO: 6. The resulting vector plasmid is hereafter referred to as pXC1-Δ350-mGM-CSF, and any resulting viral particles produced therefrom are hereafter referred to as Ad-Δ350-mGM-CSF.

10

**[00150]** An additional modified pXC1 vector plasmid was generated that had a deletion of 8 nucleotides corresponding to nucleotides 467-474 of SEQ ID NO: 2 (which correspond to nucleotides 468-475 of SEQ ID NO: 8), which included the TATA box in the E1a promoter.

15

The mutated vector plasmid is hereafter referred to as pXC1-TATA, and any resulting viral particles produced therefrom are hereafter referred to as Ad-TATA. The nucleotide sequence of the 5' end of pXC1-TATA, up to the start codon of the E1a gene, is shown in SEQ ID NO: 21. The nucleotide sequence of the 5' end of Ad-TATA, up to the start codon of the E1a gene, is shown in **FIG. 1B** and SEQ ID NO: 15.

20

**[00151]** An additional modified pXC1 vector plasmid was generated that had a deletion of 9 nucleotides corresponding to nucleotides 422-430 of SEQ ID NO: 2 (which correspond to nucleotides 423-431 of SEQ ID NO: 8), which included the CAAT box in the E1a promoter. The mutated vector plasmid is hereafter referred to as pXC1-CAAT, and any resulting viral particles produced therefrom are hereafter referred to as Ad-CAAT. The nucleotide sequence of 25 the 5' end of pXC1-CAAT, up to the start codon of the E1a gene, is shown in SEQ ID NO: 22. The nucleotide sequence of the 5' end of Ad- CAAT, up to the start codon of the E1a gene, is shown in **FIG. 1C** and SEQ ID NO: 16.

25

**[00152]** An additional modified pXC1 vector plasmid was generated that had a deletion of 9 nucleotides corresponding to nucleotides 422-430 of SEQ ID NO: 2 (which correspond to 30 nucleotides 423-431 of SEQ ID NO: 8), which included the CAAT box in the E1a promoter, and a deletion of 8 nucleotides corresponding to nucleotides 467-474 of SEQ ID NO: 2 (which

correspond to nucleotides 468-475 of SEQ ID NO: 8), which included the TATA box in the E1a promoter. The mutated vector plasmid is hereafter referred to as pXC1-CAAT-TATA, and any resulting viral particles produced therefrom are hereafter referred to as Ad-CAAT-TATA. The nucleotide sequence of the 5' end of pXC1-CAAT-TATA, up to the start codon of the E1a gene, is shown in SEQ ID NO: 23. The nucleotide sequence of the 5' end of Ad-CAAT-TATA, up to the start codon of the E1a gene, is shown in **FIG. 1D** and SEQ ID NO: 17.

5 [00153] An additional modified pXC1 vector plasmid was generated that had a deletion of 9 nucleotides corresponding to nucleotides 422-430 of SEQ ID NO: 2 (which correspond to nucleotides 423-431 of SEQ ID NO: 8), which included the CAAT box in the E1a promoter, and a deletion of 4 nucleotides corresponding to nucleotides 471-474 of SEQ ID NO: 2 (which correspond to nucleotides 472-475 of SEQ ID NO: 8), which included the four nucleotide TATA sequence of the TATA box in the E1a promoter (hereafter referred to as the minimal TATA or mTATA deletion). The mutated vector plasmid is hereafter referred to as pXC1-CAAT-mTATA, and any resulting viral particles produced therefrom are hereafter referred to as Ad-CAAT-mTATA. The nucleotide sequence of the 5' end of pXC1-CAAT-mTATA, up to the start codon of the E1a gene, is shown in SEQ ID NO: 25. The nucleotide sequence of the 5' end of Ad-CAAT-TATA, up to the start codon of the E1a gene, is shown in **FIG. 1E** and SEQ ID NO: 26.

10 [00154] An additional modified pXC1 vector plasmid was generated that had a deletion of 50 nucleotides corresponding to nucleotides 194-243 of SEQ ID NO: 2 (which corresponds to nucleotides 195-244 of SEQ ID NO: 8 and nucleotides -304 to -255 upstream of the E1a initiation site) which renders E1a expression cancer-selective (as previously described in U.S. Patent No. 9,073,980). The mutated vector plasmid is hereafter referred to as pXC1- TAV-255, and any resulting viral particles produced therefrom are hereafter referred to as Ad- TAV-255. 15 Where indicated, pXC1- TAV-255 was further modified to carry a SalI site at the start site of the E1b-19k region and an XhoI site 200 base pairs 3' of the SalI site to facilitate insertion of therapeutic transgenes, as described above. The resulting vector plasmid is hereafter referred to as pXC1-TAV -Δ19k, and any resulting viral particles produced therefrom are hereafter referred to as Ad-TAV-Δ19k.

20 25 [00155] The various modified pXC1 plasmids were cotransfected with the plasmid pJM17 in HEK-293A cells to allow homologous recombination to rescue recombinant virus. Virus was

collected and underwent two rounds of plaque purification and sequencing to test for presence of the corresponding deletion as necessary.

**Example 2: E1a Expression From Ad-Δ350 In Normal And Cancerous Cells**

**[00156]** This Example describes a comparison between viral protein expression from the

5 modified adenovirus Ad-Δ350 in cancerous and normal cells.

**[00157]** Panc1 cells (human pancreatic cancer cells) and WI-38 cells (non-cancerous human lung fibroblasts) were infected with Ad-Δ350 or Ad-TAV-255 viruses, prepared as described in Example 1. E1a expression was assayed by Western blot at the indicated hours after infection.

**[00158]** As depicted in **FIGS. 2A and 2B**, following infection with the Ad-Δ350 virus, WI-

10 38 cells expressed the adenoviral protein E1a at lower levels and later time points than Panc1 cells.

**[00159]** Panc1 cells and A549 cells (human lung cancer cells) were infected with Ad-TAV-255 or Ad-Δ350 at a multiplicity of infection (MOI) of 3 or 5 and E1a expression was assayed by Western blot 72 hours after infection. As depicted in **FIG. 3A** (Panc1 cells) and **FIG. 3B**

15 (A549 cells), both cancer cell lines support high levels of E1a expression from the Ad-Δ350 or Ad-TAV-255 viruses.

**[00160]** Together, these results show that a 200 nucleotide region in Ad5, including the E1a TATA box, is required for E1a expression in non-cancerous cells, while this region is dispensable for E1a expression in tumor cells.

20 **Example 3: Cytotoxicity From Ad-Δ350, Ad-CAAT, Ad-TATA, Ad-CAAT-TATA, And Ad-CAAT-mTATA In Normal And Cancerous Cells**

**[00161]** This Example describes a comparison between cytotoxicity resulting from the modified adenoviruses Ad-Δ350, Ad-CAAT, Ad-TATA, Ad-CAAT-TATA, and Ad-CAAT-mTATA in cancerous and normal cells.

25 **[00162]** HCT116 cells (human colon cancer cells), Panc1 cells, and A549 cells were infected with Ad-Δ350, prepared as described in Example 1. Cells were infected at the indicated MOI or kept as non-infected controls and stained with crystal violet, which stains viable cells blue at the indicated times after infection. As depicted in **FIG. 4A**, each of the cancerous cell lines showed extensive cell death from four to five days after infection.

**[00163]** A panel of cancerous cell lines were infected with Ad-CAAT, Ad-TATA, Ad-CAAT-TATA, or Ad-CAAT-mTATA, prepared as described in Example 1. The panel included A549, Panc1, HCT116, Hep3b, ADS-12m ASPC 1, HT-29, and MeWo cells. Cells were infected at an MOI of 5 and stained with crystal violet 3-4 days after infection. As a control, the 5 cell lines were either cultured without infection or infected with the previously described oncolytic virus Ad-TAV-Δ19k. Results are shown in **FIGS. 5-11**. All human cancerous cell lines showed extensive cell death after infection, particularly by five days after infection, while the mouse cell line ADS-12 showed variable cell death after infection with each of the viruses.

**[00164]** Non-cancerous MRC5 cells (human lung fibroblasts) and WI38 cells were infected 10 with Ad-Δ350 or Ad-TAV prepared as described in Example 1. Cells were infected at the indicated MOI and stained with crystal violet ten days after infection. As depicted in **FIG. 4B**, as opposed to the cancerous cells that were killed within 4-5 days post infection, the non-cancerous cells remained viable as late as 10 days after infection.

**[00165]** Non-cancerous WI38 cells were infected with Ad-CAAT, Ad-TATA, Ad-CAAT-TATA, Ad-Δ350, and Ad-TAV-Δ19k, prepared as described in Example 1, at 3 and 5 MOI and 15 stained with crystal violet at four days (**FIG. 12**) or six days (**FIG. 13**) after infection. The results demonstrate that there was minimal cytotoxicity after infection for each virus.

**[00166]** Together, these results show that a 200 nucleotide region in Ad5, including the E1a 20 TATA box, is required for Ad5-mediated cytotoxicity in non-cancerous cells, while this region is dispensable for Ad5-mediated cytotoxicity in tumor cells. Similarly, Ad5 viruses with deletions in the E1a promoter of either the TATA box alone, the CAAT box alone, or both the TATA and CAAT boxes showed cancer-selective cytotoxicity.

#### **Example 4: Therapeutic Transgene Expression From Ad-Δ350 In Normal And Cancerous Cells**

**[00167]** Adenoviruses carrying the Δ350 deletion were further investigated for their 25 potential to be armed with a therapeutic transgene in place of the viral E1b-19k gene. The following viruses were generated as described in Example 1: the virus Ad-Δ350-Δ19k, which carries the Δ350 deletion and has the 19k region deleted without the subsequent insertion of any transgene; the virus Ad-Δ350-mGM-CSF, which carries the Δ350 deletion and carries the 30 gene for mouse GM-CSF cloned into the E1b-19k region between Sall and XhoI; and the virus

Ad-TAV- Δ19k, which carries the TAV-255 deletion and has the 19k region deleted without the subsequent insertion of any transgene.

**[00168]** Cancerous Panc1 cells, A549 cells, and ADS12 cells (mouse lung carcinoma) were infected with Ad-Δ350-Δ19k at the indicated MOI and stained with crystal violet five days

5 after infection. As depicted in **FIG. 14**, the cancerous cell lines were killed in a dose-dependent manner.

**[00169]** Cancerous Panc1 cells, A549 cells, and ADS12 cells were infected with Ad-Δ350-mGM-CSF at the indicated MOI and stained with crystal violet five days after infection. As shown in **FIG. 15**, the virus carrying the gene for mouse GM-CSF retained oncolytic activity.

10 **[00170]** A549, HCT116, Hep3b, and MeWo cells were infected with Ad-Δ350-mGM-CSF, Ad-Δ350-Δ19k and Ad-TAV-Δ19k at an MOI of 5 and stained with crystal violet at 3 to 5 days after infection. As shown in **FIGs. 16-21**, Ad-Δ350-mGM-CSF maintained cytolytic activity comparable to Ad-Δ350-Δ19k and Ad-TAV-Δ19k.

15 **[00171]** A549 cells were infected with Ad-Δ350-Δ19k, or Ad-Δ350-mGM-CSF viruses at 10 MOI. Conditioned media four days after infection was used in an ELISA for mGM-CSF. As shown in **FIG. 22**, Ad-Δ350-mGM-CSF induced expression of mGM-CSF.

20 **[00172]** ADS12 cells were infected with Ad-Δ350-Δ19k or Ad-Δ350-mGM-CSF at the indicated MOI, and conditioned media four days after infection was used in an ELISA for mGM-CSF. As shown in **FIG. 23**, Ad-Δ350-mGM-CSF induced expression of mGM-CSF in this mouse cancer cell line.

**[00173]** Together, these results show that a 200 nucleotide region in Ad5, including the E1a TATA and CAAT boxes, is required for therapeutic transgene expression from an E1b-19k expression site in non-cancerous cells, while this region is dispensable for therapeutic transgene expression from an E1b-19k expression site in tumor cells.

25 **Example 5: Anti-Cancer Activity Of Ad-Δ350**

**[00174]** This Example describes the anti-cancer activity of recombinant adenoviruses with TATA box and/or CAAT box deletions produced as described in Example 1.

**[00175]** Mice (strain 129S4) were injected subcutaneously with ADS-12 cells (mouse lung cancer) and allowed to form tumors. After tumors reached a volume of approximately 50-100

mm<sup>3</sup> the mice were randomized to treatment with Ad-Δ350-Δ19k, Ad-TAV-Δ19k (as a positive control for an effective oncolytic virus), or the buffer (as a negative control). The mice were dosed with intratumoral injections of the indicated treatment given every four days for three doses. As shown in **FIG. 24**, mice treated with the buffer had rapid tumor growth while mice  
5 treated with either Ad-Δ350-Δ19k or Ad-TAV-Δ19k had reductions in their tumor size and in many cases no detectable remaining tumors.

**[00176]** This results suggest that Ad-Δ350-Δ19k, carrying a deletion that removes both the CAAT box and the TATA box of the promoter for the viral E1A gene, is effective cancer treatment.

10 **Example 6: TATA box deletion in Ad35**

**[00177]** This Example describes the production of recombinant type 35 (Ad35) adenoviruses with deletions in the E1a promoter region that include a TATA box.

**[00178]** The E1a promoter of adenovirus type 35 (Ad35) contains a TATA box at nucleotides corresponding to nucleotides 477 to 484 of SEQ ID NO: 24. A recombinant Ad35  
15 adenovirus was generated with the TATA box deleted by conversion of the natural sequence of  
TTTTACGTAGGTGTCAGCTGATCGCTAGGGTATTTACCTCAGGGTTGTCAAGAGGCCA  
CTCTT (SEQ ID NO: 18; TATA box underlined)

to

TTTTACGTAGGTGTCAGCTGATCGCTAGGGCCTCAGGGTTGTCAAGAGGCCACTCTT  
20 (SEQ ID NO: 19).

**[00179]** HEK-293 cells were transfected with genomes for the TATA-deleted Ad35 virus and, as show in **FIG. 25**, developed a cytopathic effect indicative of viral growth. These results suggest that a recombinant Ad35 adenovirus was generated with the TATA box deleted may be suitable as an oncolytic virus.

**INCORPORATION BY REFERENCE**

**[00180]** The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.

**EQUIVALENTS**

5   **[00181]** The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and the range of equivalency of the  
10   claims are intended to be embraced therein.

What is claimed is:

1. A recombinant virus comprising: (i) a modified TATA box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative cell; and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative cell.
- 5 2. A recombinant virus comprising a modified TATA box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative cell.
- 10 3. A recombinant virus comprising a modified CAAT box-based promoter operably linked to a gene, wherein the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative cell.
4. The recombinant virus of any one of claims 1-3, wherein the recombinant virus is selected from a recombinant vaccinia virus, adenovirus, adeno-associated virus (AAV), herpes simplex virus 1 (HSV1), myxoma virus, reovirus, poliovirus, vesicular stomatitis virus (VSV), measles virus (MV), and Newcastle disease virus (NDV).
- 15 5. The recombinant virus of claim 4, wherein the recombinant virus is a recombinant adenovirus.
- 20 6. The recombinant virus of claim 5, wherein the recombinant virus is selected from a type 5 adenovirus and a type 35 adenovirus.
7. The recombinant virus of claim 6, wherein the adenovirus is a type 5 adenovirus.
8. The recombinant virus of any one of claims 1-2 or 4-7, wherein the modified TATA box-based promoter is an early gene promoter.
- 25 9. The recombinant virus of claim 8, wherein the modified TATA box-based promoter is an E1a promoter, E1b promoter, or E4 promoter.
10. The recombinant virus of claim 9, wherein the modified TATA box-based promoter is an E1a promoter.

11. The recombinant virus of any one of claims 1-2 or 4-10, wherein the modification included in the modified TATA box-based promoter comprises a deletion of the entire TATA box.

12. The recombinant virus of any one of claims 1-11, wherein the virus comprises a 5 deletion of nucleotides corresponding to -27 to -24 of the E1a promoter.

13. The recombinant virus of claim 12, wherein the virus comprises a deletion of nucleotides corresponding to -31 to -24 of the E1a promoter.

14. The recombinant virus of claim 13, wherein the virus comprises a deletion of nucleotides corresponding to -44 to +54 of the E1a promoter.

10 15. The recombinant virus of claim 14, wherein the virus comprises a deletion of nucleotides corresponding to -146 to +54 of the E1a promoter.

16. The recombinant virus of any one of claims 1-11, wherein the virus comprises a deletion of nucleotides corresponding to 472 to 475 of the Ad5 genome (SEQ ID NO: 8).

15 17. The recombinant virus of claim 16, wherein the virus comprises a deletion of nucleotides corresponding to 468 to 475 of the Ad5 genome (SEQ ID NO: 8).

18. The recombinant virus of claim 17, wherein the virus comprises a deletion of nucleotides corresponding to 455 to 552 of the Ad5 genome (SEQ ID NO: 8).

19. The recombinant virus of claim 18, wherein the virus comprises a deletion of nucleotides corresponding to 353 to 552 of the Ad5 genome (SEQ ID NO: 8).

20 20. The recombinant virus of any one of claims 1-19, wherein the virus comprises a polynucleotide deletion that results in a virus comprising the sequence CTAGGACTG (SEQ ID NO: 7), AGTGCCCCG (SEQ ID NO: 12) and/or TATTCCCCG (SEQ ID NO: 13).

21. A recombinant virus, wherein the virus is a type 5 adenovirus comprising a deletion of nucleotides corresponding to -27 to -24 of the E1a promoter region.

25 22. The recombinant virus of claim 21, wherein the virus comprises a deletion of nucleotides corresponding to -31 to -24 of the E1a promoter region.

23. The recombinant virus of claim 22, wherein the virus comprises a deletion of nucleotides corresponding to -44 to +54 of the E1a promoter region.

24. The recombinant virus of claim 23, wherein the virus comprises a deletion of nucleotides corresponding to -146 to +54 of the E1a promoter region.

25. A recombinant virus, wherein the virus is a type 5 adenovirus comprising a deletion of nucleotides corresponding to 472 to 475 of the Ad5 genome (SEQ ID NO: 8).

5 26. The recombinant virus of claim 25, wherein the virus comprises a deletion of nucleotides corresponding to 468 to 475 of the Ad5 genome (SEQ ID NO: 8).

27. The recombinant virus of claim 26, wherein the virus comprises a deletion of nucleotides corresponding to 455 to 552 of the Ad5 genome (SEQ ID NO: 8).

28. The recombinant virus of claim 27, wherein the virus comprises a deletion of 10 nucleotides corresponding to 353 to 552 of the Ad5 genome (SEQ ID NO: 8).

29. A recombinant virus, wherein the virus is a type 5 adenovirus, wherein the virus comprises a polynucleotide deletion that results in a type 5 adenovirus comprising the sequence CTAGGACTG (SEQ ID NO: 7), AGTGCCCC (SEQ ID NO: 12), or TATTCCCC (SEQ ID NO: 13).

15 30. A recombinant virus, wherein the virus is a type 5 adenovirus, wherein the virus comprises a polynucleotide deletion that results in a type 5 adenovirus comprising the sequence CTAGGACTG (SEQ ID NO: 7).

31. The recombinant virus of any one of claims 1 or 3-20, wherein the modified CAAT box-based promoter is an early gene promoter.

20 32. The recombinant virus of claim 31, wherein the modified CAAT box-based promoter is an E1a promoter, E1b promoter, or E4 promoter.

33. The recombinant virus of claim 32, wherein the modified CAAT box-based promoter is an E1a promoter.

25 34. The recombinant virus of any one of claims 1, 3-20, or 31-33, wherein the modification included in the modified CAAT box-based promoter comprises a deletion of the entire CAAT box.

35. The recombinant virus of any one of claims 1-34, wherein the virus comprises a deletion of nucleotides corresponding to -76 to -68 of the E1a promoter.

36. The recombinant virus of any one of claims 1-34, wherein the virus comprises a deletion of nucleotides corresponding to 423 to 431 of the Ad5 genome (SEQ ID NO: 8).

37. The recombinant virus of any one of claims 1-36, wherein the virus comprises a polynucleotide deletion that results in a virus comprising the sequence TTCCGTGGCG (SEQ ID NO: 14).

38. A recombinant virus, wherein the virus is a type 5 adenovirus comprising a deletion of nucleotides corresponding to -76 to -68 of the E1a promoter region.

39. A recombinant virus, wherein the virus is a type 5 adenovirus comprising a deletion of nucleotides corresponding to 423 to 431 of the Ad5 genome (SEQ ID NO: 8).

10 40. A recombinant virus, wherein the virus is a type 5 adenovirus, wherein the virus comprises a polynucleotide deletion that results in a type 5 adenovirus comprising the sequence TTCCGTGGCG (SEQ ID NO: 14).

41. The recombinant virus of any one of claims 1-40, wherein the virus comprises a deletion of nucleotides corresponding to 477 to 484 of the Ad35 genome (SEQ ID NO: 24).

15 42. A recombinant virus, wherein the virus is a type 35 adenovirus comprising a deletion of nucleotides corresponding to 477 to 484 of the Ad35 genome (SEQ ID NO: 24).

43. The recombinant virus of any one of claims 1-42, wherein the modification included in the modified TATA box-based promoter or CAAT box-based promoter does not comprise an addition of or a substitution with a separate, functional promoter sequence.

20 44. The recombinant virus of any one of claims 1-43, further comprising a nucleotide sequence encoding a therapeutic transgene.

45. The recombinant virus of claim 44, wherein the therapeutic transgene encodes a therapeutic polypeptide selected from an oncoprotein, tumor suppressor polypeptide, enzyme, cytokine, immune modulating polypeptide, antibody, lytic peptide, vaccine antigen, 25 polypeptide which complements genetic defects in somatic cells, and a polypeptide which catalyzes processes leading to cell death.

46. The recombinant virus of claim 44, wherein the therapeutic transgene encodes a therapeutic polypeptide selected from an apoptotic agent, antibody, CTL responsive peptide, cytokine, cytolytic agent, cytotoxic agent, enzyme, heterologous antigen expressed on the

surface of a tumor cell to elicit an immune response, immunostimulatory or immunomodulatory agent, interferon, lytic peptide, oncoprotein, polypeptide which catalyzes processes leading to cell death, polypeptide which complements genetic defects in somatic cells, tumor suppressor protein, vaccine antigen, and any combination thereof.

- 5 47. The recombinant virus of claim 44, wherein the therapeutic transgene encodes a therapeutic polypeptide selected from acetylcholine, an anti-PD-1 antibody heavy chain or light chain, an anti-PD-L1 antibody heavy chain or light chain, BORIS/CTCFL, CD19, CD20, CD80, CD86, CD137L, CD154, DKK1/Wnt, ICAM-1, IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-17, IL-23, IL-23A/p19, interferon-gamma, TGF- $\beta$ , a TGF- $\beta$  trap, FGF, IL-24, IL-27, IL-35, MAGE, NY-ESO-1, p53, and thymidine kinase.
- 10 48. The recombinant virus of claim 44, wherein the therapeutic transgene encodes a TGF- $\beta$  trap.
49. The recombinant virus of claim 44, wherein the therapeutic transgene encodes a therapeutic nucleic acid selected from an antisense RNA and a ribozyme.
- 15 50. The recombinant virus of any one of claims claim 44-49, wherein the adenovirus comprises an E1b-19K and an E1b-55K start site, and wherein the nucleotide sequence encoding the therapeutic transgene is inserted between the start site of E1b-19K and the start site of E1b-55K.
- 20 51. The recombinant virus of any one of claims 1-50, wherein the recombinant virus selectively replicates in a hyperproliferative cell.
52. The recombinant virus of any one of claims 1-51, wherein the recombinant virus selectively replicates in a non-growth arrested cell.
53. The recombinant virus of any one of claims 1-52, wherein the recombinant virus selectively has cytolytic activity in a hyperproliferative cell.
- 25 54. The recombinant virus of any one of claims 1-53, wherein the recombinant virus selectively has cytolytic activity in a non-growth arrested cell.
55. The recombinant virus of any one of claims 5-54, wherein the recombinant virus selectively expresses E1a and/or E1b in a hyperproliferative cell.

56. The recombinant virus of any one of claims 5-55, wherein the recombinant virus selectively expresses E1a and/or E1b in a non-growth arrested cell.

57. The recombinant virus of any one of claims 44-56, wherein the recombinant virus selectively expresses the therapeutic transgene in a hyperproliferative cell.

5 58. The recombinant virus of any one of claims 44-57, wherein the recombinant virus selectively expresses the therapeutic transgene in a non-growth arrested cell.

59. The recombinant virus of any one of claims 1-58, wherein the hyperproliferative cell is a cancer cell, endothelial cell, epidermal cell, fibroblast, and/or immune cell.

60. The recombinant virus of claim 59, wherein the hyperproliferative cell is a cancer cell.

10 61. The recombinant virus of claim 60, wherein the cancer cell is selected from the group consisting of an anal cancer, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, gynecologic cancer, head and neck cancer, 15 hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer and thyroid cancer cell.

20 62. The recombinant virus of claim 60, wherein the cancer cell is selected from a lung cancer cell, a colon cancer cell, and a pancreatic cancer cell.

63. A recombinant virus comprising a modified or deleted viral regulatory sequence that permits selective expression of the virus in a hyperproliferative cell.

25 64. A pharmaceutical composition comprising the recombinant virus of any one of claims 1-63 and at least one pharmaceutically acceptable carrier or diluent.

65. A method of expressing a therapeutic transgene in a target cell comprising exposing the cell to an effective amount of the recombinant virus of any one of claims 44-63 to express the target transgene.

66. A method of inhibiting proliferation of a tumor cell comprising exposing the cell to an effective amount of the recombinant virus of any one of claims 1-63 to inhibit proliferation of the tumor cell.

67. A method of inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject to an effective amount of the recombinant virus of any one of claims 1-63 to inhibit proliferation of the tumor.

68. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of the recombinant virus of any one of claims 1-63 to treat the cancer in the subject.

69. The method of claim 68, wherein the cancer is selected from melanoma, squamous cell carcinoma of the skin, basal cell carcinoma, head and neck cancer, breast cancer, anal cancer, cervical cancer, non-small cell lung cancer, mesothelioma, small cell lung cancer, renal cell carcinoma, prostate cancer, gastroesophageal cancer, colorectal cancer, testicular cancer, bladder cancer, ovarian cancer, hepatocellular carcinoma, cholangiocarcinoma, brain cancer, endometrial cancer, neuroendocrine cancer, merkel cell carcinoma, gastrointestinal stromal tumors, a sarcoma, and pancreatic cancer.

70. The method of claim 68, wherein the cancer is selected from anal cancer, basal cell carcinoma, bladder cancer, bone cancer, brain cancer, breast cancer, carcinoma, cholangiocarcinoma, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastroesophageal cancer, gastrointestinal (GI) cancer, gastrointestinal stromal tumor, hepatocellular carcinoma, gynecologic cancer, head and neck cancer, hematologic cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, merkel cell carcinoma, mesothelioma, neuroendocrine cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, pediatric cancer, prostate cancer, renal cell carcinoma, sarcoma, skin cancer, small cell lung cancer, squamous cell carcinoma of the skin, stomach cancer, testicular cancer and thyroid cancer

71. The method of claims 67-70, wherein the recombinant virus is administered in combination with one or more therapies selected from surgery, radiation, chemotherapy, immunotherapy, hormone therapy, and virotherapy.

72. A method of treating a hyperproliferative disease in a subject in need thereof, the method comprising administering to the subject an effective amount of the recombinant virus of any one of claims 1-63 to treat the hyperproliferative disease in the subject.

73. The method of claim 72, wherein the hyperproliferative disease is selected from atherosclerosis, rheumatoid arthritis, psoriasis, lupus, idiopathic pulmonary fibrosis, sclerodermapulmonary hypertension, asthma, kidney fibrosis, COPD, cystic fibrosis, DIP, UIP, macular degeneration, restenosis, retinopathies, hyperproliferative fibroblast disorders, scleroderma, glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, transplant rejection, glomerulopathies and cirrhosis.

74. The method of claim 72, wherein the hyperproliferative disease is selected from atherosclerosis, rheumatoid arthritis, psoriasis, lupus, idiopathic pulmonary fibrosis, scleroderma and cirrhosis.

75. The method of any one of claims 65-74, wherein the effective amount of the recombinant virus is  $10^2$ - $10^{15}$  plaque forming units (pfus).

76. The method of any one of claims 67-75, wherein the subject is a human.

77. A method of engineering an oncolytic virus, the method comprising modifying a viral TATA box-based promoter operably linked to a gene such that the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative cell.

78. A method of engineering an oncolytic virus, the method comprising modifying a viral CAAT box-based promoter operably linked to a gene such that the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative cell.

79. A method of engineering an oncolytic virus, the method comprising modifying a viral TATA box-based promoter operably linked to a gene such that the modified TATA box-based promoter lacks a functional TATA box and permits selective expression of the gene in a hyperproliferative cell and/or modifying a viral CAAT box-based promoter operably linked to a gene such that the modified CAAT box-based promoter lacks a functional CAAT box and permits selective expression of the gene in a hyperproliferative cell.

80. An isolated nucleic acid comprising a nucleotide sequence selected from SEQ ID NO: 3, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23.

81. An isolated nucleic acid comprising a nucleotide sequence of SEQ ID NO: 3.

5 82. The isolated nucleic acid of claim 81, wherein the isolated nucleic acid comprises the nucleotide sequence of SEQ ID NO: 4.

83. A host cell comprising the isolated nucleic acid of any one of claims 80-82.

84. A method of producing a recombinant virus comprising:

10 (a) growing the host cell of claim 83 under conditions to produce the recombinant virus; and

(b) purifying the recombinant virus.

85. The method of any one of claims 65-76, wherein the method further comprises measuring an immune response to an antigen in the subject.

86. The method of any one of claims 65-76 or 85, wherein the effective amount of the 15 recombinant virus is identified by measuring an immune response to an antigen in the subject.

87. The method of claim 85 or 86, wherein the immune response to the antigen is measured by injecting the subject with the antigen at an injection site on the skin of the subject and measuring the size of an induration at the injection site.

**FIG. 1A**

CATCATCAATAATACCTTATTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT  
 GTGACGTGGCGCGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG  
 TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTGGTGTGC  
 GCCGGTGTACACAGGAAGTGACAATTTCGCGCGGTTAGGCGGATGTTGTAGTAAATTG  
 GCGTAACCGAGTAAGATTGCCATTTCGCGGGAAAAGTGAAATAAGAGGAAGTGAAATCT  
 GAATAATTGTGTTACTCATAGCGCTAATATTGTCTAGGGCCGCGGGACTTGACCGT  
 TTACGTGGAGACTCGCCCAGGTGTTTCTCAGGTGTTCCCGCGTCCGAAAGTTGG  
 CGTTTATTATTAGTCAGCTGACGTGAGTGCCTCAAGAGGCCACTCT  
 TGAGTGCCAGCGAGTAGAGTTCTCCGAGCCGCTCCGACACCGGGACTGAAAATG  
 (SEQ ID NO: 3)

**FIG. 1B**

CATCATCAATAATACCTTATTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT  
 GTGACGTGGCGCGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG  
 TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTGGTGTGC  
 GCCGGTGTACACAGGAAGTGACAATTTCGCGCGGTTAGGCGGATGTTGTAGTAAATTG  
 GCGTAACCGAGTAAGATTGCCATTTCGCGGGAAAAGTGAAATAAGAGGAAGTGAAATCT  
 GAATAATTGTGTTACTCATAGCGCTAATATTGTCTAGGGCCGCGGGACTTGACCGT  
 TTACGTGGAGACTCGCCCAGGTGTTTCTCAGGTGTTCCCGCGTCCG-TGGCGTTTA  
 TTATTATAGTCAGCTGACGTGAGTGTATTACCCGGTGAGTTCAAGAGGCCACTCT  
 TGAGTGCCAGCGAGTAGAGTTCTCCGAGCCGCTCCGACACCGGGACTGAAAATG  
 (SEQ ID NO: 15)

**FIG. 1C**

CATCATCAATAATACCTTATTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT  
 GTGACGTGGCGCGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG  
 TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTGGTGTGC  
 GCCGGTGTACACAGGAAGTGACAATTTCGCGCGGTTAGGCGGATGTTGTAGTAAATTG  
 GCGTAACCGAGTAAGATTGCCATTTCGCGGGAAAAGTGAAATAAGAGGAAGTGAAATCT  
 GAATAATTGTGTTACTCATAGCGCTAATATTGTCTAGGGCCGCGGGACTTGACCGT  
 TTACGTGGAGACTCGCCCAGGTGTTTCTCAGGTGTTCCCGCGTCCG-TGGCGTTTA  
 TTATTATAGTCAGCTGACGTGAGTGTATTACCCGGTGAGTTCAAGAGGCCACTCT  
 TGAGTGCCAGCGAGTAGAGTTCTCCGAGCCGCTCCGACACCGGGACTGAAAATG  
 (SEQ ID NO: 16)

**FIG. 1D**

CATCATCAATAATACCTTATTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT  
 GTGACGTGGCGCGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG  
 TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTGGTGTGC  
 GCCGGTGTACACAGGAAGTGACAATTTCGCGCGGTTAGGCGGATGTTGTAGTAAATTG  
 GCGTAACCGAGTAAGATTGCCATTTCGCGGGAAAAGTGAAATAAGAGGAAGTGAAATCT  
 GAATAATTGTGTTACTCATAGCGCTAATATTGTCTAGGGCCGCGGGACTTGACCGT  
 TTACGTGGAGACTCGCCCAGGTGTTTCTCAGGTGTTCCCGCGTCCG-TGGCGTTTA  
 TTATTATAGTCAGCTGACGTGAGTGTGAGTGCCTCAAGAGGCCACTCTGAGTGC  
 CAGCGAGTAGAGTTCTCCGAGCCGCTCCGACACCGGGACTGAAAATG (SEQ ID NO:  
 17)

**FIG. 1E**

CATCATCAATAATACCTTATTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT  
GTGACGTGGCGCGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG  
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTGGTGTGC  
GCCGGTGTACACAGGAAGTGACAATTTCGCGCGGTTAGGCGGATGTTGTAGTAAATTG  
GGCGTAACCGAGTAAGATTGGCCATTTCGCGGGAAAAGTGAAATAAGAGGAAGTGAAATCT  
GAATAATTGTGTTACTCATAGCGCGTAATATTGTCTAGGGCCGCGGGACTTGACCGT  
TTACGTGGAGACTCGCCCAGGTGTTTCTCAGGTGTTCCCGCGTCCG-TGGCGTTTA  
TTATTATAGTCAGCTGACGTGAGTGTATT-CCCGGTGAGTCCTCAAGAGGCCACTCTGA  
GTGCCAGCGAGTAGAGTTCTCCGAGCCGCTCCGACACCGGGACTGAAAATG (SEQ ID  
NO: 26)

**FIG. 1F**

CATCATCAATAATACCTTATTTGGATTGAAGCCAATATGATAATGAGGGGGTGGAGTTT  
GTGACGTGGCGCGGGCGTGGGAACGGGGCGGGTGACGTAGTAGTGTGGCGGAAGTGTGATG  
TTGCAAGTGTGGCGGAACACATGTAAGCGACGGATGTGGCAAAAGTGACGTTTGGTGTGC  
GCCGGTGTACACAGGAAGTGACAATTTCGCGCGGTTAGGCGGATGTTGTAGTAAATTG  
GGCGTAACCGAGTAAGATTGGCCATTTCGCGGGAAAAGTGAAATAAGAGGAAGTGAAATCT  
GAATAATTGTGTTACTCATAGCGCGTAATATTGTCTAGGGCCGCGGGACTTGACCGT  
TTACGTGGAGACTCGCCCAGGTGTTTCTCAGGTGTTCCCGCGTCCG~~GGTCAAAGT~~TGG  
CGTTTATTATAGTCAGCTGACGTGAGTGTATT~~TATA~~CCCGGTGAGTCCTCAAGAGG  
CCACTCTTGAGTGCCAGCGAGTAGAGTTCTCCGAGCCGCTCCGACACCGGGACTGAA  
AATG (SEQ ID NO: 27)

FIG. 2A











FIG. 2B





**FIG. 3A****FIG. 3B**


**FIG. 4A****FIG. 4B**


**FIG. 5**


**FIG. 6**


**FIG. 7**


**FIG. 8**

**FIG. 9**

**FIG. 10**

**FIG. 11**

**FIG. 12**

**FIG. 13**




**FIG. 14**

FIG. 15




**FIG. 16**


CN Ad-Δ350-Δ19K Ad-Δ350-mGMCSF Ad-TAV-Δ19K



**FIG. 17**


CN Ad-Δ350-Δ19K Ad-Δ350-mGMCSF Ad-TAV-Δ19K



**FIG. 18**


**FIG. 19**

CN Ad-Δ350-Δ19K Ad-Δ350-mGMCSF Ad-TAV-Δ19K



**FIG. 20**

CN      Ad-Δ350-Δ19K    Ad-Δ350-mGMCSF    Ad-TAV-Δ19K



**FIG. 21**

CN Ad-Δ350-Δ19K Ad-Δ350-mGMCSF Ad-TAV-Δ19K





FIG. 22






**FIG. 23**

FIG. 24



**FIG. 25**



**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:
  - a. (means)  
 on paper  
 in electronic form
  - b. (time)  
 in the international application as filed  
 together with the international application in electronic form  
 subsequently to this Authority for the purposes of search
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2018/016025

## A. CLASSIFICATION OF SUBJECT MATTER

A61K 35/76 (2015.01) C12N 15/86 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PATENW, CAPLUS, BIOSIS, EMBASE, MEDLINE: Keywords: TATA box, Goldberg Hogness, CAAT box, CAT box, GGCCAATCT or CCAAT, modify, delete, non-functional, lack function, oncolytic, cytotytic, tumor, cancer, hyperproliferative, selective, specific, virus, adenovirus, AAV, HSV, reovirus, poliovirus, vsv, mv, ndv, recombinant, heterologous, transgene, engineer; CPC & IPC symbols: A61K 35/76, C12N 15/86 and similar terms/symbols

GENOMEQUEST: SEQ ID NO: 3, 7, 12, 13, 14, 15, 16, 17, 20, 21, 22, 23

ESPACENET, PUBMED, Internal Databases: Applicant and Inventor names

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	Documents are listed in the continuation of Box C	

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search  
21 May 2018Date of mailing of the international search report  
21 May 2018

## Name and mailing address of the ISA/AU

AUSTRALIAN PATENT OFFICE  
PO BOX 200, WODEN ACT 2606, AUSTRALIA  
Email address: pct@ipaaustralia.gov.au

## Authorised officer

Anita Cochrane  
AUSTRALIAN PATENT OFFICE  
(ISO 9001 Quality Certified Service)  
Telephone No. +61262832118

INTERNATIONAL SEARCH REPORT		International application No.
C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		PCT/US2018/016025
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2010/086838 A2 (ONCOS THERAPEUTICS) 05 August 2010 Abstract, Figure 3, pages 6, 14, 19-21 & 24	1-19, 21-28, 31-36, 38-39, 41-42, 44-77, 79 & 85-87
X	EP 3006566 A1 (ONCOS THERAPEUTICS LTD.) 13 April 2016 Figure 1, pages 4, 11 & 19	21-28, 35-36, 38-39, 41-42, 44-76 & 85-87
X	HEDJRAN F et al, "Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b", <i>Cancer Gene Therapy</i> , 2011, 18: 717-723 Abstract, Figure 2 & page 719	38-39, 41-50, 63-76 & 85-87
X A	WO 2010/101921 A2 (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 10 September 2010 Figure 4, pages 4, 13, 39 & 44 page 39	38-39, 41-50, 63-76 & 85-87 50
A	HANAKA S et al, "Regulation of In Vitro and In Vivo Transcription of Early-Region IV of Adenovirus Type 5 by Multiple <i>cis</i> -Acting Elements" <i>Molecular and Cellular Biology</i> , 1987, 7: 2578-2587 Abstract, page 2580	
A	NISHIGAKI T et al, "A Specific Domain of the Adenovirus E1V Promoter is Necessary To Maintain Susceptibility of the Integrated Promoter to E1A Transactivation", <i>Molecular and Cellular Biology</i> , 1988, 8: 353-360 Abstract	
Form PCT/ISA/210 (fifth sheet) (July 2009)		

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2018/016025**

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<b>Patent Document/s Cited in Search Report</b>		<b>Patent Family Member/s</b>	
<b>Publication Number</b>	<b>Publication Date</b>	<b>Publication Number</b>	<b>Publication Date</b>
WO 2010/086838 A2	05 August 2010	WO 2010086838 A2	05 Aug 2010
		AU 2010209334 A1	08 Sep 2011
		BR PI1008159 A2	29 Mar 2016
		CA 2750770 A1	05 Aug 2010
		CN 102325887 A	18 Jan 2012
		EP 2391722 A2	07 Dec 2011
		EP 2391722 B1	11 Jun 2014
		FI 20095751 A	03 Aug 2010
		FI 121574 B	14 Jan 2011
		JP 2012516682 A	26 Jul 2012
		KR 20110110371 A	06 Oct 2011
		RU 2011136280 A	10 Mar 2013
		SG 173502 A1	29 Sep 2011
		US 2012063995 A1	15 Mar 2012
EP 3006566 A1	13 April 2016	EP 3006566 A1	13 Apr 2016
		EP 2783005 A1	01 Oct 2014
		FI 20116181 A	26 May 2013
		FI 123955 B	15 Jan 2014
		US 2015232811 A1	20 Aug 2015
		US 9410129 B2	09 Aug 2016
		US 2016082100 A1	24 Mar 2016
		WO 2013076374 A1	30 May 2013
WO 2010/101921 A2	10 September 2010	WO 2010101921 A2	10 Sep 2010
		EP 2403951 A2	11 Jan 2012
		EP 2403951 B1	30 Sep 2015
		EP 3029144 A1	08 Jun 2016
		JP 2012519014 A	23 Aug 2012
		JP 6072414 B2	01 Feb 2017
		JP 2016028035 A	25 Feb 2016
		KR 20110122866 A	11 Nov 2011
		KR 101752910 B1	30 Jun 2017
		KR 20170077278 A	05 Jul 2017
		SM T201500329 B	25 Feb 2016

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

Form PCT/ISA/210 (Family Annex)(July 2009)

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2018/016025**

This Annex lists known patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

<b>Patent Document/s Cited in Search Report</b>		<b>Patent Family Member/s</b>	
<b>Publication Number</b>	<b>Publication Date</b>	<b>Publication Number</b>	<b>Publication Date</b>
		US 2011318311 A1	29 Dec 2011
		US 9073980 B2	07 Jul 2015
		US 2016017294 A1	21 Jan 2016

**End of Annex**